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Abbreviations 
ACs Articular chondrocytes 
BM Bone marrow 
BMSCs Bone marrow derived mesenchymal stromal cells 
bTGFß3 Biotinylated TGFß3 
CC Chondrogenic differentiation capacity 
ChM Chondrogenic medium 
CM Complete medium (with 10 % FBS) 
COL Collagen 
DGA Differential gene expression analysis 
ECM Extracellular matrix 
FG Fast green 
GAG Glycosamino glycan 
HM Hypertrophic medium 
hu human 
IF Immunofluorescence 
IHC Immunohistochemistry 
ms mouse 
NCs Nasal chondrocytes 
OM Osteogenic medium 
P passage 
PEG Poly(ethylene glycol) 
SafO SafraninO 
TE Tissue engineering 
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Summary 
There is the need of alternative treatment strategies for osteochondral injuries that include a defect 
of articular cartilage and the underlying bone. Human bone marrow derived mesenchymal stromal 
cells (BMSCs) due to their ease of isolation and multipotent differentiation capacity have been 
investigated for a long time as cell source candidate for osteochondral tissue engineering. 
However, their clinical application has been hampered by several limitations most importantly such 
as intrinsic tendency to acquire a (pre-) hypertrophic chondrogenic phenotype leading to 
endochondral ossification in vivo, lack of spatial control of the differentiated cell phenotypes and 
vast donor-to-donor variability, as well as unpredictability of differentiation outcome potentially due 
to the crude isolation procedure and lack of selective markers.  
 
Part I of the thesis addressed the optimization of the protocol to generate endochondral bone by 
BMSCs and the assessment of the formation of bone-cartilage composites by combination of 
BMSCs with nasal chondrocytes (NCs). To this end, an enzymatically cross-linked and cell-
degradable poly(ethylene glycol) (PEG) based hydrogel system served as a scaffolding material. 
By functionalization of the hydrogel with TGFß3 employing an affinity binding strategy, 
encapsulated BMSCs were induced to undergo endochondral ossification resulting in the efficient 
formation of ossicles including a cortical rim and bone marrow upon immediate subcutaneous 
implantation in immunocompromised mice. This demonstrated that the otherwise needed lengthy 
in vitro culture step can be circumvented. In bi-layered hydrogels endochondral ossification of 
BMSCs occurred similarly to the single-layered configuration, while NCs formed cartilaginous 
tissue, however, unexpectedly acquired hypertrophic features under the influence of the TGFß3 
from the BMSC-layer. Replacing TGFß3 with BMP-2 allowed the formation of an osteochondral 
construct including hyaline cartilage corroborating the potential of our approach to generate 
cartilage-bone composites. In future, these bi-layered gels need to be tested in an orthotopic 
model with special focus on how an interface closely resembling the native one can be generated. 
 
Part II of the thesis aimed at elucidating the existence of an expanded BMSC subpopulation with 
superior chondrogenic differentiation potential. It was hypothesized that retrospective analysis of 
single clones with high chondrogenic capacity have a different gene expression profile than clones 
with low capacity and that differential gene expression would guide to prospectively isolate 
superior chondrogenic potential clones from bulk BMSCs. For one of the tested donors a 
segregation of clones of high and low CC based on their transcriptomic profile could be observed. 
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Comparison of sorted multiclonal BMSCs based on CD56/NCAM1 - the most promising surface 
marker identified by the transcriptomic analysis - in chondrogenic in vitro culture assays showed a 
trend of better chondrogenesis in the CD56+ cells, however, it necessitates confirmation with 
additional donors. In a further analysis of clones from other donors, intra-donor variability 
compromised the revelation of transcriptional signatures of clones with high versus low 
chondrogenic capacity.  In future, RNA sequencing as well as cell sorting are required to be 
performed at earlier time points to exclude confounding effects from extensive cell expansion. 
Ultimately, identification of a cell subset with superior chondrogenic potential may aid to develop 
improved BMSC based osteochondral tissue engineering approaches. 
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1 Introduction 
1.1 Articular cartilage 
1.1.1 Structure 
Articular cartilage, a connective tissue of hyaline cartilage type covers the bone surface of 
diarthrodial joints. Its major function is to transmit load and to allow smooth articulation of the 
joints. It is composed of extracellular matrix (ECM) mainly based on collagens and proteoglycans 
and is scarcely populated by one cell type, the chondrocyte. Articular cartilage is not vascularized 
and does not contain nerves. The nutrition happens solely through diffusion from the synovial 
space or the subchondral bone plate [1].  
 
Articular cartilage has a zonal organization (Figure 1), from top to bottom there is the superficial 
(SZ), the middle/transitional (TZ), the deep/radial zone (RZ), the calcified cartilage (CC), the 
subchondral bone plate (SB) and the subchondral spongiosa. The line visible in H&E staining 
between the RZ and the calcified cartilage is called tidemark (T). The whole structure is a few 
millimeters thick. From the SZ to the RZ the cell density decreases, in the SZ the cells have a 
flattened, whereas in the other zones the cells have a rounded morphology and in the RZ they are 
arranged in columns of 5-8 cells oriented perpendicular to the joint surface. The content of 
glycosamino glycan (GAGs) increases from the surface to the deeper zones, as well as the 
thickness of the collagen fibers, which are parallel to the surface in the SZ, of mixed orientation in 
the TZ and perpendicular to the surface in the RZ [2].  
 
The ECM can be divided into three regions, depending on the distance to the chondrocyte, the 
pericellular, the territorial matrix and the interterritorial matrix forming the largest region. Collagens 
(Col) mainly of type II and marginally of type I, IV, V, VI, IX, and XI account for 60% of the dry 
weight of the articular cartilage ECM [1]. Collagens have a very specific protein structure, namely 
they are composed of a repetitive Gln-Pro-hydroxyPro-tripeptide alpha-chain forming triple helices, 
which arrange in fibers of 50-110 µm in diameter from the SZ to the RZ as measured by scanning 
electron microscopy [3]. Proteoglycans contribute 10-15 % to the dry weight of the ECM. They are 
composed of small protein cores heavily decorated with long linear GAGs of up to 100 
monosaccharides. Due to their high negative charge they are responsible for the high osmotic 
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pressure within articular cartilage and thereby providing it with high physical strength. The main 
proteoglycan in articular cartilage is aggrecan [1].  
 
Figure 1: Zonal organization of articular cartilage. A) Human articular cartilage from the femoral condyle stained with 
McNeil’s Tetrachrome, basic Fuchsine and Toluidine Blue O, scale bar: 500 µm. On the left the average thicknesses of 
the respective layers are indicated in mm (adapted from [2]). B) Schematic drawing of articular cartilage. SZ: superficial 
zone, TZ: transitional zone, RZ: radial zone, T: tidemark, CC: calcified cartilage, SB: subchondral bone, BM: bone 
marrow, PM: pericellular matrix, TM: territorial matrix, IM: interterritorial matrix.  
 
1.1.2 Development 
During limb development two different cartilage types are formed, i) the stable articular cartilage 
and ii) the transient cartilage of the cartilage anlage and the growth plate that is eventually 
replaced by bone tissue (Figure 3). The development of articular cartilage is linked to joint 
formation, which morphologically manifests first in the so-called interzone. It is a cell band 
interrupting the cartilaginous condensations at the prospective joint sites that is demarcated by 
down-regulation of chondrogenic genes such as ColII and Sex-Determining Region Y-Box 9 
(Sox9), as well as up-regulation of growth differentiation factor 5 (GDF-5) (a member of the bone 
morphogenetic protein (BMP) superfamily), wingless-type MMTV integration site family 9a (Wnt9a) 
and Wnt4, and the BMP antagonists chordin and noggin [4-6] (Figure 3C). The precise molecular 
mechanisms governing the induction of interzone formation are not completely known yet. Clearly, 
Wnt signaling, in particular Wnt9a secreted from interzone cells, plays an important role since its 
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ectopic application caused heterotopic joint-like structures [7, 8]. However, it has been 
demonstrated that Wnt is not a requisite for joint induction, but rather it is involved in the regulation 
of joint integrity by inhibiting chondrogenesis and by regulating indian hedgehog (Ihh) expression 
[9]. Ihh in turn is not only involved in controlling the phenotype of growth plate chondrocytes, but it 
also seems to be implicated in joint formation [10]. Additionally, tight regulation of BMP signaling is 
crucial for joint formation [11]. Lineage tracing studies demonstrated that articular cartilage and the 
other joint related structures, but not growth plate cartilage, directly originate from GDF-5+ 
interzone cells [12]. Later, conditional lineage tracing of the progeny of GDF-5+ cells revealed that 
joint development necessities a continuous influx of cells contributing to the GDF-5 lineage, since a 
single tamoxifen administration was insufficient to label all joint cells at late embryonic days [13]. 
These experiments also showed that through the temporal induction of new GDF-5+ cells the 
lineage divergence is controlled. Early traced interzone cells contributed to different joint tissues 
than temporally later traced ones, which developed to articular chondrocytes [13, 14]. What is the 
driver of the temporal lineage specification and the precise population of cells replenishing the 
GDF-5+ interzone cells still remains elusive. In contrast, Ray et al. demonstrated by pulse-chase 
DNA-labeling experiments and lineage tracing of the progeny of ColII+ cells that the proliferating 
chondrocytes within the cartilage anlage not only contribute to transient chondrocytes, but also to 
the proliferation deficient interzone cells and proposed that inhibition of BMP signaling by noggin 
expressed by cells directly next to the presumptive joint site directed this lineage segregation [15] 
(Figure 3D). Articular cartilage adopts its unique structure postnatal, it is controversial whether cell 
proliferation plays a role [16] or if it is rather governed by cellular rearrangements and cell volume 
increase [14]. 
 
Whether we can extrapolate from the precise understanding of the development, more specifically 
from how the lineage bifurcation into stable and transient cartilage is decided, to treatment 
strategies advancing cartilage regeneration remains to be answered. 
 
1.1.3 Repair and current treatment strategies 
Cartilage has very limited self-repair capacities due to its avascular nature, low proliferative activity 
of resident chondrocytes and dense ECM network not allowing for cell migration. Articular cartilage 
injuries are classified according to how deep the injury penetrates the tissue. In partial thickness 
defects, the injury affects the tissue above the tidemark, in full thickness defects the subchondral 
bone plate is exposed and in osteochondral defects the injury goes beyond the subchondral bone 
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plate and can even penetrate the subarticular spongiosa [17]. Lack of treatment or insufficient 
repair can cause the degenerative disease osteoarthritis that leads to functional loss of the joint 
articulation. Interestingly, by analysis of the degree of post-translational modifications of cartilage 
ECM proteins Catterall et al. observed that in human osteoarthritic knee cartilage the modified to 
unmodified collagen ratio was much lower than in osteoarthritic hip suggesting that knee cartilage 
is biologically “younger” than hip cartilage thanks to a higher repair response by producing more 
new ECM protein. This study suggested the existence of intrinsic healing responses at least in 
certain joints; the very important question remaining is how they can be enhanced in order to 
prevent joint degeneration [18]. 
 
Surgical interventions to treat articular cartilage injuries include bone marrow stimulatory 
techniques, which allow the formation of a bone marrow clot at the defect site, mosaic plasty that 
encompasses the transfer of osteochondral pieces from a less weight bearing region, or the 
implantation of previously harvested and expanded articular chondrocytes directly (ACI, 
autologous chondrocyte implantation (ACI)) or with the help of a collagen and/or GAG based 
scaffold, (matrix associated ACI ((MACI)) [19]. Mosaic plasty is not often applied because of limited 
donor site availability and very high donor site morbidity. Bone-marrow stimulatory techniques, as 
well as the implantation of ACs often result in the formation of fibrocartilage that is rich in ColI and 
has inferior mechanical properties, hence can induce osteoarthritis. Moreover, for the treatment 
based on autologous ACs the donor site morbidity and the need for a two-step surgical procedure 
is also an issue [20]. Meta-reviews comparing ACI with microfracture procedures did not reveal 
whether one technique is superior over the other [21, 22]. Neither did various clinical studies show 
whether one technique is better than the other in a certain scenario [20]. Absence of consent is 
based on different reasons, mainly maybe due to lack of standardization. A promising approach for 
an alternative treatment strategy is tissue engineering (TE) (described in section 1.3.2) by e.g. 
using an alternative cell source with reduced donor site morbidity such as MSCs harvested from 
the bone marrow (discussed in section 1.3.2.1.2). 
 
If there is only one defect with a size smaller than 1 cm in an otherwise healthy human (knee) joint, 
it can heal. Also in animal models there are the non-critical-size defects. Although, a recent study 
in rat demonstrated that even small defects that healed on short term could cause joint wide 
alterations such as increased catabolism and subchondral bone plate advancement at later time 
points [23]. Are these defects filled thanks to increased anabolic activity of the neighboring cells 
eventually concomitant with limited proliferation? If yes, what are the stimuli for them and why do 
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they lack or are insufficient in critical size defects? Or are there specific cells in the articular 
cartilage or the neighboring tissues such as the synovium or the infra-patellar fat pad that could be 
activated to contribute to repair? What is more, what is the precise origin of the cells forming repair 
tissue (sometimes stated to be very good) in small and pre-clinical animal models if acellular 
materials are implanted in critical-size defects? E.g. to date, a number of studies have addressed 
the use of acellular natural or synthetic scaffolds decorated with growth and/or chemotactic factors 
in order to improve the homing of endogenous cells for cartilage regeneration [24-26]. Studies 
assessing the effectiveness of repair between material-based treatments of defects with and 
without subchondral bone involvement (it is important to differentiate the two scenarios, since in 
the latter case bone marrow derived progenitor cells have facilitated access to the injury site) 
should be combined with cell tracing studies in order to find out which cells exactly are attracted by 
the diverse functionalized scaffolds implanted. A few studies have recently led to the identification 
of putative joint progenitor cells. They were defined based on characterization of the joint site by 
looking for slow-cycling proliferative cells and for numerous stem cell markers, as well as specific 
traits e.g. transforming growth factor beta receptor (TGFßR) II [27] or proteoglycan (Prg) 4 
expression [16] in combination with in vitro colony-forming-unit and differentiation assays. These 
cells localized to various joint tissues such as the superficial zone of articular cartilage, the infra-
patellar fat pat, the synovium and the groove of ranvier, and were shown to persist also in the 
(young) adult organism [6].  
 
1.2 Bone  
1.2.1 Structure 
Bone gives mechanical structure to soft tissues, houses hematopoiesis and controls blood calcium 
levels. It has a hierarchical structure (Figure 2). Macroscopically there is cortical (compact) and 
trabecular (cancellous) bone. The ends of long bones consist of a cortical rim and a trabecular 
interior at the epiphysis and cortical bone at the diaphysis, while flat bones have a shelf of cortical 
bone and a trabecular interior. Trabecular bone is less dense, more porous and the lamellae are 
more irregularly distributed than in cortical bone. The lamellae are sheets of mineralized ColI fibers 
that in cortical bone are centrally arranged around the haversian canal containing nerves, blood 
and lymphatic vessels and together form the osteon [28]. During development and bone healing 
upon endochondral ossification woven bone (primary bone) is formed first. It is characterized by 
rapid calcification, thinner collagen fibers and overall a less organized structure of the lamellae. 
Later it is remodeled into secondary (compact and cancellous) bone [29]. The primary cell that 
 14 
builds up the bone ECM is the osteoblast. It develops from mesenchymal precursors and either 
once embedded into the mineralized matrix it becomes an osteocyte or at the bone rim it stays as 
a quiescent bone lining osteoblast. The osteocytes are star-shaped cells with long extrusions that 
allow cell-cell communication through gap junctions. They sense the mechanical status of the 
surrounding bone and guide remodeling by osteoclasts. Osteoclasts, monocyte-derived 
multinucleated cells acidify the microenvironment in order to dissolve the hydroxyapatite crystals 
and secrete various enzymes such as metalloprotease 9 (MMP9) or cathepsin K to degrade the 
decalcified ECM [30]. ColI, the major organic component of bone, arranges as fibrils in arrays and 
may play a role, although not fully elucidated yet, in initiation of the formation and in governing the 
orientation and size of hydroxyapatite crystals [31]. Other ECM proteins are osteopontin, 
osteocalcin or bone sialoprotein (BSP) that are implicated in cell-ECM interactions and also play a 
role in bone mineralization [32]. 
 
Figure 2: Hierarchical organization of bone. Cortical bone is composed of osteons that in the middle contain blood 
vessels and nerve fibers and contain the lamella in which the connected osteocytes reside and are built up by calcified 
ColI fibers. These fibers are aggregates of collagen fibrils which in turn are aggregates of collagen triple helices (adapted 
from [28]).  
 
1.2.2 Development 
Bone tissue has three different embryonic origins and develops trough two different processes. 
While the bones of the extremities develop from lateral plate mesoderm, ribs and the vertebra 
originate from rostral paraxial mesoderm through the somites and the craniofacial bones mainly 
develop from neural crest cells descending from the neuroectoderm. The first two undergo 
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endochondral ossification (Figure 3), in which first a cartilage template is formed that is 
subsequently remodeled into bone and the latter undergoes mainly intramembranous (direct) 
ossification, which lacks the cartilage intermediate step [33].  
 
1.2.2.1 Endochondral ossification 
The transfer of different parts of the chicken limb bud to ectopic sites led to the identification of two 
different organizing cell centers within the limb bud. The apical ectodermal ridge (AER) at the distal 
tip governs the specification of the proximal-distal axis, and the zone of polarizing activity (ZPA) 
within the posterior mesenchyme determines the anterior-posterior axis [34-36]. The AER secretes 
fibroblast growth factors (FGFs) and Wnts, the inner mesenchymal cells produce BMP-4 and its 
inhibitor Gremlin-1 (Grem1) and the main signal of the ZPA is sonic hedgehog (Shh). Initial high 
levels of mesenchymal BMP-4 induce Grem1 expression that allows the secretion of the FGFs by 
the AER, which in turn initiates the secretion of Shh by the ZPA. Shh keeps the Grem1 levels high, 
while BMP-4 decreases and allows the AER to produce more FGF initiating an intricate loop that 
connects the two axes of the limb and additionally is responsible for digit number specification. It 
terminates (automatically) because of progenitor cell proliferation causing a shift out of the 
influence of the morphogens [37]. The mesenchymal cells under the influence of the AER stay 
undifferentiated and proliferate (Figure 3A). As soon as they are not under the influence of the 
AER anymore the chondrogenic program by high BMP-4 and consequently Sox9 activity can be 
induced [38] (Figure 3B). Deletion of Sox9 in pre-condensating mesenchyme showed that the 
transcription factor is necessary to establish the osteochondropogenitor lineage, since in absence 
of it, the limb bud mesenchymal cells were stuck [39]. After condensation and induction of ColII 
and aggrecan, Sox9 in concert with other transcription factors such as Sox5 and 6 drives 
chondrogenesis by further inducing expression of chondrogenic ECM genes and by supporting the 
proliferation of the newly formed chondrocytes [39]. This applies for the inner cells, while the outer 
rim stays uncommitted and forms the perichondrium, which is a few cell layers thick and which with 
the formation of the primary ossification center (POC) becomes the periosteum.  
 
Ihh specifically expressed by pre-hypertrophic chondrocytes together with parathyroid related 
protein (PTHrP) expressed by the perichondrium at the distal tip establish a negative feedback 
loop that governs proliferation and differentiation of the chondrocytes and thereby controls pre- and 
postnatal bone growth [40]. The chondrocytes within the limb bud are organized along the 
proximodistal axis as different phenotypes. From the distal to the proximal end there are resting, 
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proliferating chondrocytes arranged in columns, pre-hypertrophic chondrocytes expressing Ihh and 
the hypertrophic chondrocytes expressing ColX and being up to 8 fold bigger than the other 
chondrogenic phenotypes [41] (Figure 3D). This pattern of different chondrocyte phenotypes 
persists as the cartilaginous growth plate up to adolescence allowing long bone growth to occur. 
Against the initial notion that Sox9 inhibits hypertrophic differentiation of chondrocytes, conditional 
deletion of Sox9 through the enhancer of aggrecan demonstrated that Sox9 is not only driving 
chondrocyte proliferation and expression of major ECM molecules, but also activates expression of 
the hypertrophic marker ColX and inhibits premature osteoblast differentiation of pre-hypertrophic 
chondrocytes by inhibiting ß-catenin [42].  
 
For the establishment of the cartilage anlage angiogenesis does not play a role, in contrast the O2 
sensitive transcription factor hypoxia inducible factor 1-alpha (Hif1α) directly contributes to the 
persistent expression of Sox9 in the post-condensed mesenchyme and therefore is an important 
factor driving the transition from pre-chondrocytes to chondrocytes [43]. For the induction of bone 
tissue formation vascularization is crucial, if vascular endothelial growth factor (VEGF) was 
inhibited systemically by administration of one of its soluble receptors, the vascular pattern in 
growth plate of juvenile mice was disrupted and the remodeling into bone did not proceed, while 
the hypertrophic zone became enlarged [44]. With vascular invasion and the expression of 
Receptor Activator of NF-κB Ligand (RANKL) by hypertrophic chondrocytes, as well as matrix 
degrading MMPs (mostly MMP13) chondroclasts and osteoclasts are recruited that initiate the 
degradation of the cartilage ECM and therefore facilitate the deposition of woven bone matrix [45] 
(Figure 3E). 
 
Until recently because increased abundance of apoptotic bodies was observed in the hypertrophic 
zone, it was assumed that the majority of hypertrophic chondrocytes are removed by apoptosis 
and bone tissue is laid down exclusively from progenitors originating from the perichondrium and 
periosteum. In fact, inducible lineage tracing of ColX expressing cells (hypertrophic chondrocytes) 
showed that those cells contributed to ColI expressing osteoblasts in the primary ossification 
center and they persisted till postnatal days, as well as that during postnatal growth the 
hypertrophic chondrocytes from the growth plate also contributed to osteoblast and sclerostin 
positive osteocytes in trabecular, cortical and endosteal bone [46]. Park et al. then showed that at 
the cartilaginous-osseous junction there are small osterix (Osx) positive cells descendent of ColX+ 
cells, which were called the chondrocyte-derived osteoprogenitors (CDOPs), it was proposed that 
the large cell size loss from hypertrophic chondrocytes to the CDOP could happen through 
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autophagy [47]. The contribution of CDOPs to prenatal bone was measured to be higher than in 
postnatal bone [47]. These experiments strongly suggested that endochondral bone cells not only 
originate from the perichondrium/ periosteum, but also from hypertrophic chondrocytes throughout 
life (Figure 3E). 
 
The regulation of the transition of proliferative to hypertrophic chondrocytes is a highly complicated 
process and many more signaling molecules than the previously mentioned Ihh-PTHrP feedback 
loop have been attributed to play a role such as FGF9 and 18 expressed by perichondrial cells [48, 
49] and BMP-2 and 4 expressed by pre- and hypertrophic chondrocytes [50]. Their receptors 
BMPRIα and ß are expressed throughout all chondrogenic phenotypes and the deletion of them in 
transient chondrocytes showed that BMP signaling fosters chondrogenic differentiation by inducing 
Ihh and antagonizing FGF signaling. Furthermore, in absence of the BMP pathway the terminal 
differentiation was inhibited and osteoblastogenesis did not progress [51]. While Sox9 is the 
chondrogenic transcription factor, pre- and hypertrophic chondrocytes up-regulate Runt Related 
Transcription Factor 2 (Runx2), which directly induces the expression of hypertrophic chondrocyte 
related marker proteins such as VEGF, MMP13 and ColX [52]. In pre-osteoblasts Runx2 functions 
upstream of the transcription factor Osx, both of them are indispensable for osteoblastogenesis, 
since genetic deletion of them ablated differentiation to osteoblasts and in absence of Runx2 no 
expression of Osx was observed [53]. Osteoblastogenesis is dependent on Wnt canonical 
signaling [54], BMPs [55] and others [52]. 
 
The mechanism underlying the induction and formation of the secondary ossification center (SOC) 
is much less known then of the POC. Within the resting chondrocytes cartilage channels 
invaginate from the perichondrium that allow blood vessel ingrowth and bone progenitor 
recruitment [56]. Genetic ablation studies have demonstrated that thyroid hormone [57], various 
MMPs [56], insulin growth factor 1 (IGF-1) [58] and VEGF [59] are essential for the 
commencement of secondary ossification (Figure 3F). The resting chondrocytes around the 
cortical canals become also hypertrophic. How the regulation is governed that the adjacent 
articular cartilage is not affected by the massive cartilaginous matrix degradation with the formation 
of the SOC and what is the trigger of the resting chondrocytes to secrete high amounts of VEGF 
and finally to undergo hypertrophy is not understood yet. 
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Figure 3: Simplified schematic representation of endochondral ossification of long bones and of the 
development of articular cartilage. A) Chondrogenesis in the limb bud starts with the condensation of mesenchymal 
precursors under the influence of high BMP-4 through up-regulation of cell adhesion molecules such as NCAM1 (CD56) 
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and N-cadherin. B) Sox9 expression is induced that up-regulates chondrogenic matrix molecule expression. C) Within 
the chondrogenically differentiating limb bud the interzone forms that localizes at the prospective joint site. D) These 
GDF5+ and Sox9- interzone cells give progressively rise to all joint elements including articular cartilage (AC). At the 
same time the cartilage anlagen of the bone patterns into different phenotypes: Resting (RC), proliferating (PC), pre- and 
hypertrophic chondrocytes (PHC/HC). A tight balance of PTHrP, IHH, FGF and BMP signaling controls chondrocyte 
proliferation and maturation. E) With the ingrowth of blood vessels osteogenesis commences (primary ossification 
center, POC), perichondrial and hypertrophic chondrocytes contribute to osteoblasts. E) Shortly before birth, the joint 
cavity becomes apparent and the secondary ossification center (SOC) forms upon formation of perichondrial 
invaginations the so-called cartilage canals at the epiphysis. The growth plate persists till adolescence as long as the 
bones are growing. 
 
1.2.2.2 Intramembranous ossification 
Like endochondral, intramembranous ossification starts with the condensation of mesenchymal 
cells, but which then directly differentiate towards Runx2 positive osteoblasts and immediately 
secrete a woven bone ECM. Initial bone formation comes along with rapid proliferation of 
mesenchymal cells [60]. Day et al. observed that genetic ablation of Wnt signaling within the 
mesenchymal precursors caused ectopic chondrogenesis not only at the sites of endochondral 
ossification but also in the regions where normally intramembranous ossification occurs. Their 
experiments demonstrated that the mesenchymal population normally giving raise to direct 
ossification also has bipotential differentiation capacities and that high canonical Wnt activity 
(which was shown to be downstream of IHH signaling) decides for osteoblastogenesis instead of 
chondrogenesis [54].  
 
1.2.3 Repair and current treatment strategies 
Bone has good native healing properties. The healing process starts with bleeding at the fracture 
site resulting in hematoma formation and recruitment of inflammatory cells (platelets, macrophages 
etc.) that debride, secrete various growth and inflammatory factors; followed by vasculogenesis 
and high cell proliferation. In the inside a soft callus composed of avascular cartilage forms that 
develops into woven bone (hard callus) resembling the endochondral ossification process during 
development, while from the periosteum through intramembranous ossification directly a hard 
callus arises. The osteoblasts from the hard callus secret macrophage colony-stimulating factor 
(M-CSF) and RANKL, two major activator for osteoclasts, which execute the last step, the bone 
remodeling step, in which the woven bone is converted to cortical and trabecular bone [61, 62]. 
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One of the main questions is the origin and mechanisms of recruitment of the stem/ progenitor 
cells that contribute to soft and hard callus formation. It is thought that they originate from MSCs in 
the bone marrow, adipose tissue and the periosteum [63]. A lot of effort has been done on the 
characterization of these putative MSCs by in vitro or homeostatic in vivo studies, but not in injury 
settings. Marecic and co-worker addressed injury conditions, more particularly they investigated 
the existence of a bone progenitor cell that is particularly active and has undergone a phenotypic 
switch upon skeletal injury. They based their study on their previously identified mSSC [64] and 
indeed 7 days post-fracture this population isolated from the digested injured bone peaked. 
Compared to the same population isolated from healthy animals, the fractured population showed 
enhanced in vitro and in vivo osteogenic potential, as well as higher CFU-F frequency and less 
apoptosis. CD49f (integrin alpha 6) expression was identified to mark activated mSSC [65]. What 
mechanism activates these cells and whether that could be exploited to improve bone healing in 
non-union fractures remains the issue of future investigations. Furthermore, there is a line of 
evidence that BMSCs contributing to fracture repair keep regional information from the 
development by their specific Hox gene expression profile and that only the progenitors of the 
specific region are implicated in the fracture repair [66]. This opens a new dimension to the origin 
of the cells responding to bone injuries. It would be interesting to know, how this positional 
information by specific Hox gene expression imparts cues for differentiation and whether it has any 
relationship to the regenerative function of BMSCs in tissue engineering applications. 
 
Despite the good healing capacities of bone, there are circumstances where the regenerative 
process is impaired such as in case of congenital defects, of big bone loss due to tumor resection 
or trauma induced non-union fractures. The gold standard treatment of non-union fractures has 
been autologous bone grafting mostly with cancellous bone from the iliac crest. So far, bone 
autologous grafts have been the only bone substitute with osteogenic, osteoinductive and 
osteoconductive properties and seems to be a quite successful treatment strategy, however, there 
are limited donor site availability and diverse donor site morbidities such as chronic pain or 
infections, while cadaveric allografting suffers from increased incidence of fractures and infections 
[67, 68]. For these reasons alternative treatment options have been investigated including bone 
marrow aspirate implantation, allografting with decellularized bone chips, injection of synthetic 
calcium phosphate based materials, application of platelet rich plasma, recombinant BMP-2 or 
combinations thereof. Clinical studies including sufficient control groups have been lacking, 
therefore a putative superiority of another method over autografts could not be demonstrated so far 
[69]. Last, there remains the promising alternative of bone tissue engineering, which is discussed 
in section 1.3.3. 
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1.3 Tissue engineering (TE) 
1.3.1 Paradigm 
TE has been employed and investigated before, however in 1987 it was defined the way it is still 
applicable today, as well: “Tissue engineering is the application of the principles and methods of 
engineering and life sciences toward the fundamental understanding of structure-function 
relationships in normal and pathologic mammalian tissue and the development of biological 
substitutes to restore, maintain, or improve function.” [70] An important publication in reflecting and 
summarizing the current attempts in the science of TE that time proposed it as an alternative 
treatment strategy to organ or tissue transplantation in case of organ or tissue loss or failure [71]. 
That time highlighted important future directions of TE research are still the main focus nowadays. 
These include the thorough understanding of mechanisms driving cell differentiation, also 
particularly the role of the ECM, the identification of the most suitable cell source, effective large-
scale cell culture systems, the design of natural or synthetic biocompatible materials, including 
implementation of sustained delivery systems for biological stimulants that are able to support 
cellular functions and finally in vitro systems, which are predictive for in vivo out-comes [71].  
 
Figure 4: Tissue engineering (TE) paradigm. 
The classical TE work flow is composed of the 
following steps: harvesting stem/progenitor cells 
from a biopsy of the patient (1), isolating (2), 
expanding (3) and seeding them on a scaffold 
for in vitro directed tissue formation (4) and 
finally implanting the tissue graft back to the 
patient at the site of tissue damage (5). It can be 
altered by i) skipping the cell expansion step 
and directly seeding the isolated cells on the 
scaffold and/or by ii) circumventing the in vitro 
3D culture step by immediately implanting the 
cells within a scaffold with tissue inducing cues. 
Classically, TE is based on an 
appropriate cell source (stem/progenitor cells), a material that acts as a structural and possibly 
functional support and as a cell delivery tool, as well as a mix of soluble factors inducing 
differentiation. This can be summarized as the following paradigm (Figure 4): Cells are harvested 
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from a patient’s biopsy, expanded, seeded on a scaffold for differentiation and tissue formation in 
vitro and the resulting constructs are implanted back to the patient. For clinical settings this 
procedure is rather unpractical due to long in vitro culture times, which are connected to high cost 
and risk of contamination and which would also necessitate development of sophisticated closed, 
fully automated systems. Therefore, the paradigm was adjusted to omit the in vitro culture steps 
partially (as investigated in the frame of my thesis, see part I) or fully [72] and let the tissue directly 
develop in situ by delivering all the necessary stimuli in the scaffold. Often, retrieval of autologous 
cells necessities a surgical procedure that may be related to various side effects and risks and is 
limited by donor site availability. For that reason, the TE paradigm has been adapted even more 
rigorously by skipping the cellular part and instead implanting only an instructive material (it can be 
a synthetically processed one [73-78] or decellularized tissue [79]) that directly at the site of 
implantation induces recruitment of local stem/progenitor cells and induces their differentiation to 
build up a tissue.  
 
Unfortunately, TE in the sense of the in vitro generation of an immediate tissue replacement upon 
implantation has not led to an as broad success as postulated 25 years ago due to manifold 
reasons such as lack of standardization, reproducibility, efficacy, safety and/ or cost-effectiveness. 
But maybe most importantly insufficient understanding and inappropriate implementation of 
molecular mechanisms regulating tissue morphogenesis, growth and regeneration have led to a 
paradigm change in order to increase the robustness of TE, and to foster its clinical translation. We 
do not only speak from TE but rather about developmental engineering or even developmental re-
engineering [80, 81]. Instead of cocktails of soluble factors empirically determined, concepts known 
from the development of the underlying tissue are applied e.g. the spatiotemporally controlled 
stimulation of key signaling factors. Furthermore, they are applied with consideration of the adult 
system (e.g. the state of commitment of the adult cell source in comparison to the counterpart 
during development) and the injury setting such as mechanical parameters, oxygen tension and 
the presence of inflammation, respectively.  
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1.3.2 Cartilage tissue engineering 
1.3.2.1 Cell sources 
1.3.2.1.1 Chondrocytes 
Articular chondrocytes represent the first-choice cell source for cartilage TE. However, there is 
high donor site morbidity and due to limited biopsy size the cells have to be expanded massively 
that reduces their chondrogenic phenotype and also re-differentiation potential, which is further 
diminished with higher donor age [82].  
 
A promising alternative chondrocyte source is the nasal septum, from which nasal chondrocytes 
(NCs) can be isolated. The cartilage of the nasal septum (together with the one of the nasal lobe) 
gives stiffness to the nose and its ECM like the one of articular cartilage is mainly based on ColII, 
has a high GAG content and shows absence of ColI and only traces of ColX [83]. NCs have high 
proliferative, and robust, less donor- and age- dependent re-differentiation capacities in vitro and in 
vivo and do not cause donor site morbidity [84-86]. What is more, when in co-culture with ACs or 
implanted in joints, NCs adapted their hox gene profile, which is because of their neural crest origin 
different from the one of ACs, demonstrating their developmental plasticity [87]. In full thickness 
defects in goats engineered NC derived cartilage was found to majorly contribute to the hyaline 
cartilage repair tissue and to efficiently integrate with the subchondral bone [88].  
 
Considering the good chondrogenic differentiation capability of NCs it would be important to further 
characterize the (intra- and inter-donor) homogeneity of them and whether the tissue contains only 
fully differentiated cells or whether there are also (quiescent) progenitors present that can be 
activated to augment tissue formation even more. Interestingly, comparison of nasal septum cells 
outgrowth cultures to the more commonly enzymatically isolated NCs showed differences in terms 
of clonogenicity, migratory behavior, cell surface expression (after culture on plastic) leading the 
authors to propose them as more progenitor-like compared to the digestive cell fraction. However, 
in chondrogenic conditions these cells secreted higher amounts of ColI and did not prove to be 
more useful then the digestive fraction, at all [89]. 
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1.3.2.1.2 Bone marrow-derived stem/stromal cells (BMSCs) 
1.3.2.1.2.1 Definition 
The identity of MSCs is a highly debated topic. Already the meaning of the acronym is not clear 
and ranges from mesenchymal stromal and/ or stem cells to multipotent stem cell and moreover is 
used for cells derived from a broad range of tissue types, such as adipose tissue, bone marrow, 
umbilical cord blood, the amniotic membrane, synovial tissue, skeletal muscle, liver and heart 
tissue [90]. Most importantly, it cannot be defined by a ubiquitous surface marker phenotype, 
neither differentiation potential.  The mesenchymal and tissue stem cell committee of the 
international society for cellular therapy attempted to define minimal criteria for “the” MSCs as the 
plastic adherent cells that are after culture under standard conditions lineage negative (CD45, 
CD34, CD14 or CD11b, CD79alpha or CD19 and HLA-DR), positive for CD73, CD90 and CD105 
(>95 %) and have tri-lineage in vitro differentiation potential to adipocytes, chondrocytes and 
osteocytes [91]. However, these properties do not solve the above-mentioned issues and what is 
more, they introduce an additional problem, namely the definition of a cell purely based on in vitro 
conditions. Historically, in the 1960’s Friedenstein et al. showed that whole mouse bone marrow 
transplanted ectopically in diffusion chambers depending on the cellular density applied 
(sometimes) formed bone of host origin [92, 93]. Later, bone marrow was plated (in the specific 
case of this report on collagen gels) and the adherent cells, denoted as the stromal fraction, 
formed clones (colony-forming unit fibroblasts (CFU-F)). The clones were implanted on these 
collagen gels subcutaneously or under the renal capsule in mice and 15 % of the implanted clones 
formed a bone organ inclusive marrow or only bone tissue, respectively and the remaining ones 
just formed some kind of connective tissue [94]. Based on these experiments and others the idea 
of the bone marrow stromal stem cell was grown, which is capable to make bone, reticular, stromal 
and adipogenic tissue [95, 96]. 
   
Since then many questions arose: what is the identity of the cell in the bone marrow giving rise to 
the CFU-Fs and to different skeletal phenotypes; where is it located in situ: can a specific surface 
marker panel describe/isolate it; and does it really have self-renewing properties and therefore can 
be considered as a true stem cell? Since it is generally thought that “the” BMSC has the highest 
clonogenic property, mostly, the approach of finding prospective markers that select for the (total) 
CFU-Fs in low density cultures of CD45- bone marrow mononuclear cells (BMNCs) has been 
followed. Consequently, several single surface markers were proposed to demarcate these cells 
e.g. Stro-1 [97], CD271 [98], CD49a [99] and CD146 [100]. CD146/MCAM in the bone marrow 
localized to adventitial reticular cells of sinusoids. When these clones (consisting of all cells 
 25 
expressing CD146) were combined and implanted on hydroxyapatite carriers bone organs formed 
including bone marrow containing cells lining the sinusoids. In contrast CD146- cells were able to 
form bone, but without a hematopoietic compartment. CFU-Fs were generated from the human 
cells derived of the CD146+ ossicles, of which 100% expressed CD146. These experiments 
demonstrated that among BMNCs there are cells, which have high clonogenic properties, self-
renewal capacities, are bone forming cells, important for establishing the hematopoietic niche and 
supposedly overlapping to the CD146+ cells of mural type on sinusoids in human bone marrow 
[100]. Attempting to combine the two well-described markers CD146 and CD271, Tormin et al. 
sorted from CD45-CD271+ (0.03 % of BMNCs) the CD146+ and CD146- cells and found CFU-Fs in 
both populations. Both populations showed in vitro tri-lineage differentiation potential and 
implantation of cultured multiclonal populations with hydroxyapatite granules ectopically generated 
bone organs with bone marrow. In situ, CD271/CD146 double positive cells localized sub-
endothelial on sinusoids while the CD271 only cells were found within the endosteum. Both were 
found in close proximity with CD34+ HSCs. This proposed that there are BMSCs at different 
locations forming possibly distinct HSC niches [101]. Several other combinations of CD271+ cells 
were proposed to more selectively isolate BMSCs including MSCA-1+CD56+ [102], CD90+CD106+ 
[103], and CD140a- [104, 105]. 
 
Other groups have used the murine system to find “the” BMSC prospectively. CD140a+Sca1+ was 
found to mark the highest CFU-F cells, in vitro they had tri-lineage potential and in vivo after tail 
vein injection, the cells homed to the bone marrow and seemed to contribute to maintain the 
hematopoietic niche [106]. Coincidentally, nestin:GFP cells were observed to localize as 
perivascular non-hematopoietic, non-endothelial cell subpopulation close by to the rare 
CD150+CD48-Lin- HSCs [107]. Further investigations demonstrated that they marked a BMSC, 
since they were clonogenic, had in vitro multilineage differential potential, self-renewal capacities 
by serial transplantation experiments on hydroxyapatite carriers, HSC niche supportive functions 
and since they contributed to osteoblast lineages under homeostatic conditions [107]. On the 
search of surface markers that stain specifically nestin:GFP cells Pinho et al. discovered 
PDGFRa+CD51+ cells to be the corresponding cell population [108]. Later, a mouse skeletal stem 
cell (mSSC) was defined by AlphaV+Thy-6C3-CD105-CD200+ and isolated from collagenase 
digested femurs. Seven descendent cell phenotypes were identified giving raise to bone, cartilage 
and stroma in a hierarchical manner. Specific signals could bias the phenotype of the progeny [64]. 
Nusspaumer et al. recently investigated the appearance and frequency of the most important 
described markers of MSCs in mice over time. PDGFRa+CD51+ was the largest subset of 
mesenchymal limb cells detected in mice during development and with the highest abundance 
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shortly after birth. These cells consisted of the PDGFRa+ Sca1+ cells, the CD200+ mSSCs and a 
third cell population. The first subpopulation arose earlier in development than the CD200+ one and 
could be further divided into four populations based on CD73 and CD90 expression. Although the 
CD90- subfraction performed best in in vitro trilineage assays, the chondrogenically pre-
differentiated CD90+ cells gave raise to bone organoids upon subcutaneous implantation in nude 
mice suggesting it to be a mice counterpart of the human BMSC [109]. 
 
Several recent studies by using mouse genetic models gave valuable information about how the in 
vivo functional properties, marker phenotype of skeletogenic BMSCs and developmental origin are 
related with each other. Zhou et al. used leptin receptor (LepR) for fate mapping BMSCs in vivo. 
LeptR+ cells gave rise to almost the total CFU-F of the bone marrow, were positive for pro-HSC 
niche factors and formed skeletal lineages in vitro and upon transplantation in vivo. LepR+ cells 
were observed postnatal around sinusoids and arterioles and contributed majorly to bone and 
marrow adipocytes after fracture in adult mice, but did not contribute to cartilage during 
development [110]. Grem1 expressing cells (0.0025 % of BMNCs) were found to overlap with high 
bone marrow CFU-F. Lineage tracing of these cells originally found in the metaphysis 
demonstrated that they contributed to growth plate, articular cartilage and stromal cells during 
development and to bone and cartilage under homeostatic or fractured conditions in adult mice. 
Adipocytes did not form neither in vitro nor in vivo. Grem1+ cells did not overlap neither with 
perisinusoidal Nes:GFP, nor with LepR+ cells therefore suggesting them to be a complementary 
skeletal stem cell of a reticular type [111].  Recently, a report demonstrated that the Hox gene 
profile that plays a crucial role in patterning during development was maintained throughout 
adulthood in mesenchymal progenitors in the bone marrow and cells lining the periosteum, while in 
differentiated cells Hox expression was downregulated. Hoxa11EGFP cells overlapped with LeptR+ 
and PDGFRa+CD51+ and responded to injury by proliferation and contributed to cartilage and bone 
tissue of the callus and this in a regional specific way [66].  
 
In conclusion, there is increasing evidence that a skeletal stem cell exist in vivo. However, the 
relationship between the different multipotent stem cell types described and their contribution to 
tissue formation, hematopoietic niche formation during development, and homeostasis and 
regeneration of skeletal tissues as well as maintenance of the hematopoietic stem cell niche during 
adulthood needs further investigations. Understanding more deeply the signals governing function 
and steering differentiation of these cells may provide valuable information for therapy options in 
skeletal regeneration and hematopoietic dysfunctions. Still, in the human system no surface 
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marker combination is generally acknowledged for the prospective isolation of BMSCs and that 
may limit the successful utilization of BMSCs for TE strategies to heal bone and cartilage defects.  
 
1.3.2.1.2.2 Chondrogenic differentiation of BMSC in vitro and in vivo 
Due to their ease of isolation (by culturing non-fractionated bone marrow aspirates on plastic), high 
proliferative capacities and their osteogenic and chondrogenic differentiation potential for the last 
20 years BMSCs have been a popular cell source tested for cartilage TE approaches [81]. Most 
simply, chondrogenesis of BMSCs is triggered by centrifugation of an aliquot of 0.25-0.5x 106 cells 
and subsequent culture of these pellets under serum-free conditions in presence of TGFß1 or 3, 
ascorbic acid and dexamethasone [112] or in various scaffolds. TGFß-induced differentiation of 
BMSCs typically induces concomitant expression of hypertrophy-associated genes such as ColX, 
BSP, MMP13, ColI and osteopontin, and stable cartilage matrix genes such as ColII and aggrecan. 
If implanted subcutaneously in immunodeficient mice, BMSCs- derived cartilage unlike that of 
expanded articular chondrocytes shows phenotypic instability namely calcification and features of 
endochondral ossification [113]. While this inherent tendency to undergo hypertrophy and 
endochondral ossification can be exploited for bone TE applications (see section 1.3.3) or 
hematopoietic niche modeling [114, 115], it represents the biggest limitation for cartilage repair. So 
far, no protocol has acquainted general acceptance among the scientific community that reliably 
generates hyaline-like cartilage from BMSCs and still it is not known whether at all it is possible. 
Furthermore, the donor-to-donor variability of chondrogenic in vitro differentiation potential and 
intrinsic heterogeneity are other major issues namely, only approximately 30 % of single-cell 
derived clones have the capacity to chondrogenically differentiate [116]. 
 
How does the pre-mature hypertrophic differentiation of chondrogenically stimulated BMSCs 
observed in vitro and at ectopic sites actually relate to the chondrogenic differentiation in an 
orthotopic environment? In 2002, the first clinical trial reporting the usage of cultured BMSCs for 
the repair of a defect in the femoral condyle was reported [117]. Since then many other clinical 
trials using cultured BMSCs [117-119], fresh BM aspirate or a concentrate of fresh BM [120-123] 
were published. The main focus of these studies was the assessment of the suitability and safety 
of the cells alone and not any other parameter such as specific scaffold design or growth factor 
delivery for induction of chondrogenic differentiation. In pre-clinical models such as the sheep [124-
126], goat, horses pigs and minipigs the effect of expansion, 3D-pre-culture and or growth factor 
co-delivery was not thoroughly compared, neither. Considering the cartilage phenotype achieved in 
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the repair tissue there were no consistent results. However, rather fibrosis - increased ColI 
synthesis in the cartilaginous repair tissue- and not hypertrophic differentiation of the cells 
represented the main problem reported in the clinical trials (also when bone marrow stimulatory 
techniques were applied) and in pre-clinical models [127]. 
Underlying oncept of 
approach 
Treatment Scaffold In vitro outcome In vivo outcome 
(subcutaneous nude mice) 
Ref. 
PTHrP suppresses 
hypertrophic maturation 
during endochondral 
ossification [40] 
TGFß1 + PTHrP or 
TGFß1 and after 3 
weeks + PTHrP 
- - (pellet) 6 weeks: down-regulation 
of Col II, GAGs and Col X 
(catabolism induced?) 
4 weeks: 
calcification 
[128] 
Load bearing 
environment enhances 
cartilage ECM 
accumulation  
Dynamic 
compressive loading 
in ChM for 10 
weeks.  
Hyaluronic 
acid 
hydrogel 
10 weeks: significant 
down-regulation of Col X 
and MMP13, and 
calcification content. 
-- [129] 
Whole genome gene 
array analysis 
comparing GP with 
AC Dkk1, FRZ 
(canonical Wnt 
inhibitors) and Grem1 
enriched in AC 
TGFß1 for 1 weeks, 
and then + 
recombinant Dkk1, 
Frz or Grem1 for 2- 
4 weeks 
-- (pellet) 3 and 5 weeks: no 
inhibition of 
chondrogenesis, delay of 
calcification, significant 
down-regulation of 
hypertrophic genes 
-- [130] 
Permanent cartilage 
arises and persists at 
hypoxia, while 
endochondral 
ossification necessities 
vascular invasion [44]. 
2.5 % O2 for 5 weeks 
versus normoxia, 
(and 3 weeks 
hypoxia + 2 weeks 
normoxia) 
-- (pellet) 
for in vitro 
Alginate 
gel for in 
vivo 
5 weeks: more ECM 
synthesis, hypertrophic 
genes down-, AC- and 
glycolysis-related genes 
up regulated (continuous 
low O2 was necessary for 
the observed effects). 
5 weeks: inhibited 
calcification, no fuchsin 
positivity, no vessel 
invasion. 
[131] 
“ Transduction with 
human sFLK1 
(soluble VEGFR) 
ColI 
sponge 
No in vitro culture (no 
difference to naïve cells) 
4-12 weeks: spontaneous 
chondrogenesis, no Col X 
and no vessels observed. 
[132] 
Combination of FGF 
and Wnt that induces 
proliferation of limb bud 
mesenchymal 
progenitors [38] and 
Wnt that later drives 
osteogenesis [54]. 
Expansion phase 
with WNT3a and 
FGF2, chondrogenic 
phase with WNT 
inhibitor (IWP2) (for 
5 weeks) 
-- (pellet) 5 weeks: Expansion with 
Wnt and FGF enhanced 
chondrogenicity, IWP2 
treatment lowered 
hypertrophy (Col X 
induced, but not further 
increased from 3 to 5 
weeks) 
8 weeks: hypertrophic gene 
expression and calcification 
reduced, no bone, more Col 
II-rich cartilage. 
[133] 
Sequential stimulation 
with FGF2, 9 and 18 
(mimicking embryonic 
development) can 
obviate hypertrophy. 
2 weeks ChM, + 2 
weeks ChM + FGF9 
or 18 
-- (pellets) Pro-anabolic effect and 
reduction of hypertrophy 
mediated genes (signaling 
through FGFR3, overriding 
disadvantageous signaling 
through FGFR1), some 
differences between FGF9 
and 18 observed. 
--  [134] 
Cartilage deep zone 
maturation and 
calcification guide 
development of stable 
cartilage in the upper 
zones. 
3 weeks ChM in 
transwell insert and 
well, + 7 weeks ChM 
in transwell insert 
and HM in well 
-- 
(transwell 
cultures, 
insert 
cultured 
with ColI) 
10 weeks: mineralization 
only in the lower part, Col 
II/Col X throughout the 
construct. 
4 weeks: Calcification and 
bone formation in the lower 
part, tidemark formation is 
questionable, while there is 
cartilage with lubricin at the 
surface in the upper part 
(Col X was not assessed 
anymore). 
[135] 
Inhibition of BMP by 
noggin allows the 
formation of embryonic 
AC [15]. 
2 weeks Alk1-3 
(BMP receptors) 
inhibitor in ChM + 2 
weeks HM (only for 
in vitro) 
-- (pellet) 
for in vitro 
ColI 
sponge for 
in vivo 
2 weeks: down-regulation 
of hypertrophic genes, 
slight down-regulation of 
Colll, up-regulation of AC 
related genes, no Col X at 
protein level 4w: inhibition 
of hypertrophy maintained 
even in HM 
8 weeks: no signs of 
endochondral ossification 
(Col X and I, vascularization) 
were not observed. 
P. Oc-
chetta, 
manu-
script 
in 
prepa-
ration 
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Table 1: Summary of protocols tested in order to reduce hypertrophic differentiation of BMSCs during in vitro 
and in vivo chondrogenesis. ChM: chondrogenic medium (+ TGFß), HM: hypertrophic medium (+ glycerophosphate to 
induce calcification). Implantation was performed after the treatment described in the second row. 
Nevertheless, if an in vitro generated BMSC based chondrogenic graft should serve for 
implantation, it must not have hypertrophic traits; otherwise it would fail to contribute to functional 
articular cartilage regeneration. For that reason, several groups have tried different approaches for 
inhibiting or reducing the hypertrophic phenotype of chondrogenically differentiating BMSCs as 
summarized in Table 1. Most of these studies exploited findings from development and thus 
highlighted the potential of a developmental inspired approach, however also showed that for more 
robust outcomes the implementation of a combination of factor may be necessary. 
 
1.3.2.1.3 Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) 
Step-wise developmental-oriented protocols were devised to generate chondrocytes from 
human/mouse ESCs and/or iPSCs [136-141]. ESCs are only suited to study the minimal medium 
compositions for following the developmental steps of chondrogenic differentiation in an academic 
setting. In contrast, iPSCs that can be generated from every patient and do not have any ethical 
concerns could therefore represent a suitable cell source for cartilage repair if safety-related 
aspects had been excluded [142]. Several experimenters succeeded in controlling the 
differentiation towards stable hyaline cartilage tissue [136, 138, 141], however, even step-wise 
stimulation of PSCs did not always lead to the desired cartilage phenotype. It is not clear yet, 
following which developmental path leads to the most efficient cartilage formation and most 
particularly allows the specific differentiation to the desired cartilage phenotype.  
 
1.3.2.2 Biomaterials - Chondrogenesis in hydrogels 
Generally, biomaterials are classified based on their microstructures into sponges, microfibers, 
microspheres and hydrogels. All of these classes have been used as scaffolds in cartilage TE. 
Sponges are interconnected porous structures and are often fabricated by lyophilization of natural 
(collagens, GAGs) and synthetic polymers that are eventually cross-linked in order to improve 
mechanical stability [143]. Hydrogels of natural, synthetic or of mixed origin are particularly suitable 
biomaterials for chondrogenic cultures. They are insoluble, hydrophilic, chemically and/or 
physically cross-linked polymer 3D-matrices that are highly loaded with water and are permeable 
for solutes, thus resemble the basic ECM. They are very tunable in terms of matrix stiffness and 
functionalization in order to render them biologically active such that they are cell-degradable, cell-
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adhesive, deliver and/or sequester growth factors or small molecules. The stiffness of the hydrogel 
depends on the concentration and size of monomers used and is linked to its cross-linking density 
and its mesh size. Naturally derived hydrogels are beneficial for their intrinsic biocompatibility, but 
can vary from batch to batch. The most commonly used natural hydrogels are based on the 
macromolecular chains of repetitive disaccharide units of GAGs such as hyaluronic acid, chitosan 
and alginate or are based on proteins such as fibrin, collagen or non-natural peptides. These 
monomers either jelly via spontaneous polymerization through self-assembly or are additionally 
modified for chemical cross-linking as described later for the synthetic hydrogels [144].  
 
Synthetic hydrogels comprise poly(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA), poly(2-
hydroxethyl methacrylate) (PHEMA) and others [144] (Figure 5A). While PHEMA was one of the 
first synthetic hydrogels used in TE, PEG hydrogels are the most commonly used ones and I also 
used a hydrogel system based on PEG during my PhD thesis. Oligo(poly(ethylene glycol) fumarate 
(OPF) is an example of a PEG based oligomer to that through the fumarate a hydrolysis 
susceptible ester bond was introduced. This renders the hydrogel degradable. The polymerization 
mechanism through chemical cross-linking depends on the end functionalities introduced to the 
PEG monomers. It is either light-dependent and needs the presence of a photo initiator (PI) such 
as for radical homo-polymerization between PEG-acrylate (PEGDA) or -methacrylate monomers, 
or in radical reactions (with UV or visible light depending on the PI used) of PEG-acrylate or PEG-
norbornene with a dithiol cross-linker (Figure 5B). To avoid radical polymerization, which can be 
cytotoxic, Michael type addition is employed, where the polymerization happens spontaneously 
through nucleophilic addition between a PEG-vinyl sulfone or a -maleimide and a dithiol cross-
linker (Figure 5B) [145]. 
 
The enzymatically polymerized PEG hydrogel, used in part I of the thesis consisted of eight-armed 
(40 kPa) monomers functionalized with a glutamine donor or a lysine acceptor peptide, two 
substrates of transglutaminase factor XIII (thrombin, that naturally is implicated in blood clot 
formation). The lysine peptide contained an MMP1-sensitive stretch to render the hydrogel cell-
degradable [146]. The hydrogels can be functionalized with RGD or streptavidin (for biotinylated 
growth factor immobilization) also in a factor XIII-dependent manner (Figure 5C). At the monomer 
concentration used here (1.5 % w/v) hydrogels have a storage modulus (G’) of 94 Pa, a phase 
angle of 12.7 and according the theory of Flory-Rehner the mesh size was calculated to be 40 nm 
[147]. This hydrogel does not reach the stiffness of articular cartilage. Intended to serve only as 
temporal support for the cells to lay down new ECM a similar stiffness is not necessary [143].  
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Figure 5: Synthetic hydrogels and their cross-linking strategies. A) Basic chemical structure of the most common 
hydrogel monomers. n indicates the number of arms [144]. PEG: poly(ethylene glycol), PVA: poly(vinyl alcohol), PHEMA: 
poly(2-hydroxethyl methacrylate) (PHEMA), OPF: oligo(poly(ethylene glycol) fumarate). B) Chemical cross-linking occurs 
through chain growth (simple light-induced radical polymerization of acrylate groups) or through step growth mechanism 
(light induced radical polymerization of acrylate or norbornene with dithiol cross-linkers, or light independent Michael type 
addition (nucleophilic addition) with e.g. vinyl sulfone and a dithiol cross-linker). PI: photo initiator [145]. The chain growth 
polymerization is faster leading to less regular and less mechanically stable network structures, whereas the step growth 
polymerization has slower kinetics and leads therefore to more homogenous structures with higher mechanical stability 
[144]. C) The system used in my PhD project: 8-armed PEG (40 kDa) is functionalized through Michael type addition with 
either a glutamine (in red) containing or a lysine (in red) containing peptide that are cross-linked by transglutaminase 
factor XIII. Additionally an MMP-sensitive peptide (in bold, §: cleavage site) for cell-mediated hydrogel degradability was 
added. By adding to the hydrogel-pre-polymerization mix other functionalities such as the fibronectin derived RGD 
peptide or streptavidin the hydrogel becomes cell-adhesive or can immobilize growth factors (if biotinylated growth 
factors are added) [146, 148]. 
Degradability of the PEG hydrogel and the presence of cell-adhesive peptides or functional groups 
with affinity for cartilaginous ECM proteins were assessed whether they have beneficial effects on 
chondrogenic differentiation. Either the PEG hydrogel is degraded non-specifically through 
hydrolysis such as of ester bonds in a photo polymerized PEG-polylactic acid diacrylate hydrogel 
[149] or OPF, or in a cell-mediated manner by being cross-linked with protease-cleavable cross-
linkers [150-153]. Degradability allowed higher secretion and better distribution of ECM proteins 
and therefore fostered chondrogenesis [150, 153], while the cells survived equally well regardless 
of the degradability of the underlying hydrogel [151]. In combination with cell-adhesive peptides 
MMP-cleavable hydrogels increased cell proliferation and chondrogenesis of human BMSCs, in 
absence of the cell-adhesive peptides MMP cleavage sites did not prove to be advantageous 
[152]. Most commonly the cell-adhesive peptide RGD is incorporated in the hydrogel. It was 
originally discovered in fibronectin, but is also present in other ECM proteins and is recognized by 
almost half of all integrin receptors [154]. In four-armed MMP-sensitive PEG cross-linked by the 
GAG heparin, RGD significantly enhanced cartilage ECM deposition of porcine ACs directly 
implanted in vivo, while surprisingly the ColII binding motif CWYRGRL did not have any beneficial 
effect on matrix accumulation and distribution, but rather lowered the quality of chondrogenesis 
compared to RGD [155]. In vitro RGD induced cell spreading of human BMSCs and enhanced 
chondrogenesis, while CWYRGRL did not improve it [155]. The cell-adhesive peptide GFOGER 
found on collagens induced higher GAG secretion and higher ColII and aggrecan mRNA 
expression of BMSCs than RGD in vitro in four-armed MMP-sensitive PEG hydrogels [152]. An 
additional important parameter that can be varied in PEG hydrogels is their mechanical strength, 
stiffness, this either by varying the initial monomer concentrations, the monomer molecular weight 
(changing the arm length) or the arm number. 2D cultures of BMSCs on hydrogels with differential 
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stiffness showed a poised differentiation behavior, namely that stiffer hydrogels induced rather 
osteogenic and softer hydrogels chondrogenic or adipogenic differentiation [156]. But how is the 
more relevant 3D chondrogenesis affected by the mechanical properties of the hydrogel? In a 
study that aimed to generate an osteochondral construct in vitro by using BMSCs and PEG-
diacrylate hydrogel of a graded stiffness (a compressive modulus of 48 kPa in the cartilage, 100 in 
the interface and 345 kPa in the bone part was measured) as well as varying RGD concentrations 
and presence of chondroitin-sulfate showed that the stiffness plus the biochemical cues alone did 
not induce different MSC phenotypes; secretion of ColI, II and X was the same throughout all 
layers. However, interestingly dynamic mechanical loading reduced ColX expression. Due to the 
differential stiffness there was a lower strain in the bone part leading to higher ColX expression 
there [157]. In conclusion, the question is not whether the hydrogel should be degradable or not, 
but how fast it should be degradable. Moreover, it is not yet as clear how to adjust the stiffness of 
the hydrogel in order to achieve a significant beneficial effect on the chondrogenic phenotype while 
providing sufficient mechanical support. 
 
1.3.2.3 Growth factor delivery for chondrogenic differentiation 
For simple localized delivery of growth factors in particular hydrogels, there are currently numerous 
techniques available (Figure 6). Growth factors can be physically incorporated or most importantly 
immobilized to the hydrogel network by covalent [158] or by affinity binding [159, 160]. The 
appropriate technique depends on the cross-linking strategy used and on the particular growth 
factor to be immobilized, e.g. presence of reduced and surface accessible cysteines, sensitiveness 
to further chemical modifications or short linker distances, etc. Specific tethering of the growth 
factors allows their controlled release by e.g. utilizing MMP-sensitive linkers [161]. Cartilage is 
naturally exposed to mechanical loading, therefore, systems in which growth factor release is 
governed mechanically might open the possibility for temporally adjusted growth factor release 
after implantation. Accordingly, Moghadam et al. showed that cyclic loading of a hydrogel 
consisting of thermo sensitive nanoparticles and a physically entrapped drug triggers within a few 
minutes a temperature-mediated shrinkage of the nanoparticles that resulted in higher permeability 
of the hydrogel and thereby facilitated release of the drug [162]. Furthermore, affinity binding offers 
the possibility of manipulating the activity of the growth factor. If a receptor or a receptor derived 
peptide is incorporated in the hydrogel, it can serve to sequester growth factors [159].  
 34 
 
Figure 6: Basic growth factor immobilization in hydrogels. A) Growth factors (GFs) (naturally bearing a free cysteine 
(i) or thiolated (ii)) are immobilized covalently through Michael type addition or radical thiolene conjugation into PEGDA, -
norbornene, or -vinyl sulfone and this either directly during gelation or as a step beforehand for more controlled GF 
functionalization of the hydrogel monomers and avoiding an interference with the gelation process. In case of an 
enzymatic polymerization system the growth factor was conjugated to the enzyme substrate genetically (iii). B) GFs can 
also be indirectly immobilized through an affinity binding partner such as i) streptavidin, ii) ZZ-peptide or a GAG e.g. 
heparin. In i) GFs need to be chemically modified (biotinylated), in ii) the modification is done genetically by cloning a FC 
domain to the recombinant GF or the protein to be immobilized already contains it, while in iii) the native affinity of certain 
GFs to ECM components such as GAGs is exploited and no additional modification is necessary. Alike with direct 
binding the affinity-binding partner is incorporated into the hydrogel network during gelation or conjugated to the gel 
monomer in a previous step. C) Specific GF immobilization also aims at tuning its release. Through incorporation of 
protease sensitive linkers or based on the affinity of the GF to its binding partner the release kinetics can be adjusted.  
TGFß, the main inducer of chondrogenesis, has been tested to be immobilized in various 
hydrogels aiming at achieving a highly localized and effective growth factor delivery at the site of 
cartilage injury. McCall et al. demonstrated that the covalent incorporation of thiolated TGFß1 into 
a PEGDA-based hydrogel did not hamper its activity and was suitable to induce chondrogenic 
differentiation of human BMSCs to a similar extent or even higher compared to soluble growth 
factor application as measured by accumulated GAG and ColII staining [163]. Likewise in MMP-
degradable PEG-norbornene-based hydrogels, covalently tethered TGFß1 induced ECM secretion 
by human BMSCs - swine articular chondrocytes co-cultures within two weeks of in vitro culture 
time [153]. Sustained release of adsorbed TGFß1 from self-assembling peptide hydrogels was 
achieved and resulted in the chondrogenesis of equine BMSCs within two weeks similarly to when 
delivered soluble, but with a 10-fold lower TGFß1 concentration [164]. Re’em et al. tethered 
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TGFß1 to a sulphated alginate scaffold through affinity binding and BMSCs in there underwent 
chondrogenic differentiation in the subcutaneous pockets of nude mice within three weeks [165].  
Many experimenters thoroughly characterized the release kinetics of the factor from their scaffold 
mostly in acellular conditions. Does the factor really need to be released for biological activity and 
to what extent are the release kinetics altered when there are cells present and if the scaffold was 
implanted in vivo? How long should the cells be able to sense the provided factor(s) and what are 
the ideal concentrations; do different concentrations elicit even a different response? These are 
important points that have not been investigated sufficiently, yet. Introduction of a triple MMP-
sensitive linker to the streptavidin in the hydrogel system used here in the thesis, aimed at 
increasing biotinylated growth factor release from the hydrogel. Indeed, when BMP-2 was 
immobilized through this degradable streptavidin linker, in vitro C2C12 cells and BMSCs exhibited 
enhanced osteogenic differentiation by means of ALP expression and activity compared to when a 
non-MMP-sensitive linker was used indicating that the mode of growth factor delivery can influence 
the cell response [161]. In canonical TGFß signaling, upon ligand binding the heteromer of type I 
and II receptors (TßRI and TßRII) forms and TßRII phosphorylates TßRI, which triggers down-
stream signaling via Smad2/3 and Smad4 [166]. TßRI and II are constitutively endocytosed and 
ligand binding does not alter the dynamics of receptor internalization. It seems that ligand-
mediated endocytosis (which is only possible when the immobilized growth factor was released) is 
not necessary for TGFß signaling, however, the signaling strength can be enhanced in early 
endosomes of clathrin-mediated endocytosis, while receptors being localized to lipid rafts and 
undergoing caveolin-mediated endocytosis are prone for degradation shutting off the TGFß signal 
[166]. Thus, it seems that TGFß does not need to be released in order to be (more) active. In situ 
the plasma activity of TGFß is prolonged through non-covalent association with its latency 
associated protein (LAP) (which is called the small latent complex (SLC)) and matrix bound 
through the binding to latent TGFß binding proteins as the large LC. TGFß becomes bioactive only 
ones proteolytically or mechanically liberated from LAP [167]. Interestingly, Place et al. addressed, 
whether delivering TGFß in its form as SLC immobilized in a PEGDA cross-linked hyaluronic acid 
hydrogel thus mimicking its natural presence in the tissue, has a beneficial effect on 
chondrogenesis. Although in vitro chondrogenesis of bovine ACs was induced the cell number 
decreased and the cartilage matrix was of inferior composition compared to soluble TGFß 
stimulation suggesting that in this in vitro system the chondrocytes were not able to activate the 
latency associated TGFß sufficiently [168].  
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1.3.3 Bone tissue engineering  
Traditionally, bone has been generated through direct (intramembranous) ossification most 
commonly with BMSCs and mineralized substrates [169]. Besides BMSCs, MSCs from adipose 
tissue (ADSCs) are increasingly more investigated for bone TE applications. Isolation of adipose 
tissue by liposuction causes less donor site morbidity than harvesting a bone marrow aspirate and 
more cells can be isolated [170]. Upon expansion of collagenase digested liposuction biopsies 
ADSCs can be retrieved, they show good osteogenic differentiation capacity [171] and also 
undergo endochondral ossification after implantation of hypertrophically differentiated cell pellets at 
an ectopic site [172]. Moreover, adipose tissue has the potential of intraoperative usage; by 
enzymatic digestion of the liposuction the stromal vascular fraction can be isolated, it is a 
heterogeneous population of adipocytes, MSCs, endothelial cells and macrophages. By seeding it 
on ceramic scaffolds its utility to generate de novo bone tissue in a rat calvarial defect model and 
in osteoporotic humerus fractures in a first in human trial was demonstrated [72]. 
 
In order to overcome the limits of the direct osteogenic TE strategies by BMSCs, namely graft 
tissue necrosis due to insufficient vascularization, researcher have moved to use a more 
developmentally inspired approach and to generate bone through the endochondral route [169]. 
Chondrocytes bear intrinsic resistance to hypoxia and hypertrophic chondrocytes secrete pro-
angiogenic and pro-osteogenic factors. Studies investigating the endochondral path demonstrated 
that BMSC based constructs after chondrogenic priming in scaffold-free or -aided in vitro cultures 
remodeled spontaneously into ossicles consisting of cortical and trabecular bone and bone marrow 
mostly in ectopic [114, 115, 173-177] and also in orthotopic settings [178-180]. Several different 
scaffold systems were used, from scaffold-free relying on self-aggregation approaches over ColI 
sponges, to collagen/GAG scaffolds, calcium phosphate based carriers and Polylactic co-glycolic 
acid (PLGA). Also the applied in vitro culture protocols were variable, not only did the composition 
of the used media vary, but most importantly the culture time (2-6 weeks) and the presence of a 
switch from chondrogenic to hypertrophic conditions. It is still unclear, which timing leads to the 
most efficient outcome in vivo in terms of frank bone formation. Scotti et al. reported that more 
mature hypertrophic tissue (cultured for a longer time in vitro) resulted in more efficient ossicle 
development [114] and Yang et al. did not observe more bone formation in relation to 2, 3 or 4 
weeks of in vitro culture in ChM in PLGA, nor in hydroxyapatite/tricalcium phosphate scaffolds 
[177]. Neither it is known yet to what extent the in vitro chondrogenic differentiation capacity that 
varies largely from donor to donor, is reflected in the bone formation efficiency in vivo. From a 
translational perspective, circumventing the in vitro pre-culture step would greatly facilitate the 
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faster generation of the graft and massively reduce the production costs. Indeed, Dang et al. 
designed a system based on TGFß1-loaded gelatin micro particles allowing for a fast release by 
cell secreted collagenases and BMP-2-loaded mineral coated hydroxyapatite micro particles 
allowing a slow release due to the low dissolution rate of the mineral coat for the induction of 
undifferentiated BMSCs aggregates to undergo endochondral ossification directly after 
implantation [181]. These BMSC based cell sheaths containing the micro particles with all the 
possible growth factor combinations were after 2 days (this time was needed for the self-
aggregation process) implanted in 5 mm sized rat calvarial defects. After four to eight weeks 
clearly the dual growth factor delivered constructs performed the best as measured by µCT, the 
defect was filled 50 % with real bone and the bridging to the adjacent host bone was achieved also 
in the widest area of the defect. The BMP-2 only group reached similar levels, while the TGFß 
group showed much worse results, but still better than the empty microspheres group. Histological 
analysis demonstrated that the cells followed endochondral ossification route since ColII, I and X 
could be detected including in the control group, although to varying degrees. After eight weeks 
very little human specific ColI was observed in all the groups, also there were only a few ALU-
positive human cells left. This strongly indicated that the new bone was formed by recruited rat 
cells and that surprisingly the empty micro particle very efficiently induced spontaneous 
hypertrophic cartilage differentiation, but this was apparently not enough to trigger osteogenic 
differentiation of the attracted rat cells because after eight weeks the human cells had vanished 
[182]. In part I of the thesis we tested whether chondrogenic differentiation directly in vivo triggered 
by TGFß that is delivered with the scaffold is enough to induce endochondral ossification of 
BMSCs. In contrast to Dang et al. we do not necessitate any pre-culture (the cells could even be 
directly injected to the defect site). 
 
1.3.4 Osteochondral tissue engineering 
Osteochondral defects arise as a consequence of trauma or disease (osteochondritis dissecans, 
osteonecrosis). The main challenges for osteochondral TE are the localized induction of 
differentiation to cartilage and bone tissue, respectively, the successful integration of the two 
tissues (ideally mimicking the native junction with calcified cartilage as an intermediate tissue) and 
generally that the scaffold provide sufficient mechanical stability and/or has the ability to degrade 
concomitantly with the deposition of new ECM [17].  
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In the last 20 years, hundreds of studies have assessed cartilage-bone composites for the repair of 
osteochondral defects. In Table 2 there is a summary of 20 of these studies. Although it is a 
random selection it should represent the different approaches, which have been undertaken so far. 
Reports assessing osteochondral tissue formation only in vitro showed that a shorter individual 
pre-culture time is beneficial for improved cartilage to bone integration [183] or that a layer of non-
differentiated cells is necessary for improved integration [184]. Real osteogenic differentiation 
cannot be observed in vitro, therefore a study aiming at generating an osteochondral construct and 
stopping with in vitro results is incomplete. Studies using the subcutaneous model have failed to 
generate fully differentiated bi-layered tissues, either the cartilage was not of stable phenotype 
and/or the bone tissue was not mature yet due to suboptimal cell source selection, insufficient 
stimuli or insufficient in vivo maturation time, respectively [185-189]. Still the subcutaneous model 
would be appropriate to indicate the potential of the multilayered scaffolds and the used cell source 
to form a (properly integrated) cartilage-bone composite even in a challenging environment before 
testing it in an orthotopic set-up. Because different animal models, sizes of osteochondral defects 
and time points were selected as experimental set-up, as well as the histological evaluation 
process followed differential criteria the cross comparison of the studies at an orthotopic site is 
difficult. Nevertheless, some interesting points can be mentioned. First, studies comparing their 
scaffolds in an acellular versus a cell-laden manner and studies implanting their scaffold only in an 
acellular way in an osteochondral defect did not observe a worse outcome compared to the 
condition with cells [73-78, 190]. This means that either the seeding of the cells did not happen in a 
sufficient way, not an appropriate cell source was used or also that absence of pre-culture to form 
already a tissue might have impacted the absence of a beneficial effect of the cells on the repair 
tissue. Implantation of labeled cells in these studies would have indicated the direct contribution of 
the donor cells to the formation of the repair tissue. Furthermore, these results indicated that in 
goats and rabbit osteochondral defects host cells (of whatever origin) could be attracted 
sufficiently. Second, in studies of no pre-culture (sometimes due to absence of seeded cells) for 
the induction of localized differentiation rather the differential scaffold mechanical and material 
composition was harnessed [73, 191-193] than co-delivery of growth factors [77, 78, 194]. This 
indicates that either the physical parameters are good enough, while biochemical parameters such 
as growth factors are not necessarily needed or that the neighboring environment e.g. paracrine 
factors exert a good enough influence on the differentiation of the loaded or recruited cells. In rare 
cases it was even relied solely on the effect of the neighboring tissue, namely when the scaffold 
had a single monophasic structure [75, 190, 195]. Unfortunately, these studies did not so precisely 
assess to what extent the typical structural organization (such as ECM protein distribution) of the 
cartilage and at the interface to the bone was reproduced by the repair tissue. This actually would 
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be crucial to better understand the parameters fostering the recreation of the native structural 
features of the tissue. Third, the influence of the pre-culture, whether in 2D or 3D and in a 
combined or separated manner etc., is not fully understood, yet. He et al. observed that longer in 
vitro pre-culture in chondrogenic medium led to a better outcome [195], however it has to be noted 
that they implanted a monophasic construct. Last, it is evident that steps ahead in terms of the 
experimental design could not really be observed over the time. The absence of accordance about 
what are the necessary stimuli (physical and biochemical), the optimal pre-culture time and the 
presence or absence of what cell source might be attributed to that most of the papers focus on 
one aspect, but there is a lack of big (complete) studies comparing all these different factors for 
one model and scaffold type. 
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Ref. Cartilage Bone Interface Pre-culture In vivo Model Outcome 
 Material Cell source Material Cell source     
[183] PGA mashes Bovine 
articular 
chondrocytes 
PLGA/PEG 80:20 Bovine 
periosteal 
cells 
Suture Separate pre- culture 
in ChM and OM, resp. 
followed by 
combination in OM for 
1-4 weeks 
-- For increased integration, a less 
mature cartilaginous part is 
needed. 
[73] PGA/PLGA at 
different % + 
reinforced fibers 
(porous, two different 
stiffness) 
Goat rib 
chondrocytes 
versus no 
cells 
PGA at different % + 
bioglass or calcium 
sulfate (porous, of 
different stiffness) 
Goat rib 
chondrocytes 
versus no 
cells 
Glued together  2 days in CM Goat 
osteochondral 
defect (3x 4mm), 
16 weeks 
Good hyaline cartilage and also 
subchondral bone restoration, no 
significant difference between 
groups with and without seeded 
cells. Better healing in the 
condyle than in the patellar 
groove (lower weight-bearing 
region). Higher stiffness 
materials for the cartilage part 
proofed to be better, while for the 
bone part surprisingly the 
stiffness did not influence the 
outcome. 
[191] Two different 
hyaluronan sponges 
coated with 
fibronectin 
Rabbit 
BMSCs 
Injectable CaP -- Through 
hardening 
process of the 
CaP material 
-- Rabbit 
osteochondral 
defect (3x 3mm), 
4, 12 weeks 
Cartilage-like tissue formed. The 
CaP gave mechanical support 
that promoted chondrogenesis in 
the upper part. 
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[185] PLA  sponge  Porcine 
articular 
chondrocytes 
HA, cells seeded in 
fibrin glue 
BMP-2 
transduced 
human 
fibroblasts 
PGA polymer 
film as a barrier 
for cell migration, 
PLA as a glue 
-- Subcutaneously, 
nude mice, 
4weeks 
Bone plus bone marrow formed, 
cartilage only at the rim not 
inside the scaffold. 
[192] Collagen gel Rabbit 
articular 
chondrocytes 
ß-TCP -- Integrated 
(through 
polymerization)  
-- Rabbit 
osteochondral 
defect (4x 6mm), 
8, 12, 30 weeks 
Early to late time point, initially 
hyaline repair tissue was 
replaced by fibrocartilage. ß-TCP 
was resorbed after 12 w and 
replaced by new bone. No full 
integration with adjacent tissue. 
[74] Self-assembled ColI 
gel 
Sheep 
articular 
chondrocytes 
or no cells 
30 % ColI and 70 % 
HA 
Sheep 
articular 
chondrocytes 
or no cells 
Transition zone 
composed of 60 
% ColI and 40 % 
HA 
5 days  Sheep 
osteochondral 
defect (7x 9 mm), 
24 weeks 
Presence of cells did not 
improve cartilage and bone 
regeneration. Defects in both 
groups were filled with well-
integrated hyaline like cartilage 
and subchondral bone tissue. 
Necessity of all three layers and 
whether the ratio of ColI:HA 
could be improved remain 
elusive. 
[193] PEGDA Rabbit 
BMSCs 
Allograft bone or 13-
93 glass or porous 
tantalum metal 
-- Chemical 
attachment 
-- Rabbit 
osteochondral 
defect (3.2x 4 
mm), 6, 12 weeks 
Bioactive glass out-performed 
the other two materials in terms 
of bone-bone integration and 
(supporting) ColII positive repair 
cartilage. 
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[190] OPF hydrogels 
plus/minus gelatin 
micro particles with 
TGFß1 
Rabbit 
BMSCS or no 
cells 
OPF plus/minus 
gelatin micro 
particles with TGFß1 
Rabbit 
BMSCS or no 
cells 
None (same 
scaffold) 
-- Rabbit 
osteochondral 
defect (3x3 mm), 
12 weeks 
More subchondral trabecular 
bone with TGFß1, no 
improvement of cartilage 
properties with cells or cells and 
TGFß1 compared to the 
scaffold- only condition, rather 
more fibrous and fibrocartilage 
formation observed. 
[184] Collagen 
microspheres 
Rabbit 
BMSCs 
chondroge-
nically 
stimulated, 4 
weeks  
Collagen 
microspheres 
Rabbit 
BMSCs, 
osteogenically 
stimulated, 4 
weeks  
Combination 
through 
undifferentiated 
BMSCs 
microencapsulat
ed in collagen  
ChM and/or OM, 2, 3 
weeks 
-- Layer of undifferentiated BMSCs 
bridging the cartilage and the 
bone was necessary for a better 
interface formation. 
[194] Alginate sulfate 
(porous sponge)/ 
hydrogel with affinity-
bound TGFß1 
Human 
BMSCs (only 
for in vitro 
evaluation) 
Alginate sulfate 
(porous sponge)/ 
hydrogel with 
affinity-bound BMP-
4 
Human 
BMSCs (only 
for in vitro 
evaluation) 
Through additive 
polymerization 
(directly injected 
in defect) 
-- / OM for in vitro 
culture 
Rabbit 
osteochondral 
defect (3x3 mm), 
2-4 weeks 
After 4 weeks the defects were 
fully filled with cartilage and 
underlying woven bone. 
 
 
 
[75] Coral aragonite 
scaffold with or w/o 
drilled channels and 
with or w/o 
impregnation with 
HAc 
-- Coral aragonite 
scaffold with or w/o 
drilled channels 
-- No interface 
(one scaffold) 
-- Goat 
osteochondral 
defect (6x 8 mm), 
24 weeks 
Drilling channels and 
impregnating with HAc the 
cartilage part of the scaffold was 
pre-requisite for the regeneration 
of osteochondral tissue. Well-
integrated hyaline-like cartilage 
was formed. Scaffolds almost 
fully degraded. 
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[76] Segmented 
polyurethane, TGFß1 
or BMP-2 loaded 
microspheres 
-- PLGA  -- Integrated -- Rabbit 
osteochondral 
defect (4.5x4 
mm), 12-24 
weeks 
Slow release of the two factors 
within 6 weeks (measured in vivo 
non-invasively). Osteochondral 
tissue formed, no ColX detected 
in cartilage. No difference 
between the two growth factors. 
[186] Agarose hydrogel Porcine 
articular 
chondrocytes 
Agarose hydrogel Porcine 
BMSCs 
Through additive 
polymerization 
ChM, 3 weeks Subcutaneous 
implantation, 4 
weeks 
Calcification, ColI and X 
localized to the bony layer, 
however, time point to early to 
observe bone formation. 
Cartilage formed by 
chondrocytes. No graded 
interface. 
[77] OPF hydrogel with 
microspheres 
containing IGF-1 
-- OPF hydrogel with 
microspheres 
containing BMP-2 
-- Through additive 
polymerization 
-- Rabbit 
osteochondral 
defect (3x 3 mm), 
6, 12 weeks 
Delivery of both growth factors 
did not overtly improve the repair 
cartilage tissue compared when 
only one was delivered. Hyaline: 
fibrocartilage, 50:50 was formed, 
also in the bone part there were 
remnants of fibrous tissue, bone 
mineral density improved with 
dual growth factory delivery. 
[78] Collagen/GAG 
scaffold absorbed 
FGF-18 or BMP-7 
-- Collagen/GAG 
scaffold absorbed 
FGF-18 or BMP-7 
-- No interface 
(one scaffold) 
-- Sheep 
osteochondral 
defect (5.8x 6 
mm), 24 weeks 
FGF-18 out-performed the BMP-
7 treated scaffold. Well-
integrated hyaline cartilage was 
formed. Sometimes cartilage 
extended into the bone part. 
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[187] Agarose hydrogel or 
self-assembled 
aggregate 
Porcine 
BMSCs and 
various cell 
sources (…) 
Alginate hydrogel Porcine 
BMSCs 
? ChM, separate 
culture, 2 weeks; 
combination, 4 weeks 
Subcutaneously, 
nude mice, 6 
weeks 
BMSCs calcified in vivo, no 
stable cartilage was formed. Too 
short time point in order to see 
nice bone formation. 
[196] Polyvinyl alcohol/ 
gelatin/ vanillin 
(PVA/G/V) 
Rabbit 
BMSCS, 
chondrogenic
ally pre-
cultured 
HA- polyamide-6 Rabbit 
BMSCS, 
osteogenically 
pre-cultured 
Non porous 
PVA/G, 
integrated 
OM, 1 week  Rabbit 
osteochondral 
defect (4x 6mm), 
6, 12 weeks 
Cell seeded constructs 
performed better at 6 and 12 
weeks, the cartilage integrated 
undistinguishable with the host 
tissue, the subchondral bone as 
well. Donor cell contribution to 
tissue regeneration could be 
observed till 4 weeks, at later 
time points it was not 
investigated. 
[188] Highly porous poly (ε-
caprolactone) 
Bovine 
articular 
chondrocytes 
Highly porous poly 
(ε-caprolactone) and 
HA particles 
Bovine 
BMSCs 
Integrated -- Subcutaneously, 
nude mice, 9 
weeks 
(Good) and confined 
vascularization in bony layer, 
new bone tissue deposited 
around HA granules, 
chondrogenic matrix formed. No 
degradation/ remodeling of the 
scaffold was observed. 
[189] ColI hydrogel Human 
BMSCs 
ColI hydrogel with 
Mg/HA 
Human 
BMSCs 
Integrated 3 days, CM Subcutaneously, 
nude mice, 4, 8 
weeks 
No delamination, organized 
homogenous cell colonization, 
some hints of differentiation. 
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[195] PGA/PLA Porcine 
BMSCs 
PGA/PLA Porcine 
BMSCs 
No interface 
(one scaffold) 
ChM, 2, 4, 8 weeks Porcine 
osteochondral 
defect (10x 4 
mm), 24 weeks 
The longer cultured the 
constructs were (more scaffold 
degradation), the better the 
repair (50 % of fully repaired 
defects in the 8 week-group). 
Cartilage (even though 
hypertrophic after in vitro culture) 
and subchondral bone formed 
and integrated with host tissue – 
localized differentiation was 
governed by the environment. 
Table 2: Summary of studies assessing the performance of osteochondral grafts in vitro and in in vivo ectopic and orthotopic models. OM: osteogenic 
medium, ChM: chondrogenic medium, CM: complete medium, the composition of the media delineated with the same name might not always be equal. PGA: 
Polyglycolic acid, PLGA: Polylactic co-glycolic acid, PLA: Poly-L-lactic acid, CaP: Calcium phosphate, HA: hydroxyapatite, TCP: Tricalcium phosphate, HAc: 
hyaluronicacid.
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2 Thesis aims 
2.1 Part I: Functionalized hydrogels to engineer in vivo 
osteochondral composites by spatially controlled 
induction of endochondral ossification 
Traumatic joint injuries involving damage of articular cartilage and subchondral bone represent a 
clinical challenge with frequently unsatisfactory outcome. A promising alternative strategy to 
treat these defects could be the implantation of an engineered cartilage-bone composite. BMSC 
due to their ease of isolation, high proliferative capacities and chondrogenic and osteogenic 
differentiation potential have been extensively used for the generation of engineered grafts. 
However, the major hurdles in achieving chondrogenesis from BMSCs are their pre-mature 
adoption of a (pre-)hypertrophic phenotype that results in ossification along the endochondral 
route in an in vivo vascularized environment, and the vast donor to donor variability. 
Furthermore, the spatial organization of engineered cartilage could not be achieved, neither.  
 
Figure 7: Schematic of the experimental approach of part I. A) Initial concept of the project. RC: resting, PC: 
proliferating, HC: hypertrophic chondrocytes. B) Components of the project that were assessed effectively (numbers 
indicate chapter). For the osseous layer BMSCs were encapsulated in PEG hydrogels containing (immobilized) 
TGFß3. For the cartilaginous layer, first, BMSCs transduced with sFLK were encapsulated and the possibility of 
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immobilizing sFLK or bevacizumab to the PEG hydrogel was assessed and second nasal chondrocytes (NCs) were 
encapsulated in non-functionalized hydrogels. For the formation of a bone-cartilage composite, BMSCs in a hydrogel 
layer containing (immobilized) TGFß3 were combined with NCs in a non-functionalized second layer. All hydrogel 
constructs were implanted subcutaneously in immunocompromised mice immediately after cell encapsulation for 
evaluation of their tissue formation potential. 
During embryonic development and postnatal long bone growth the chondrocytes of the 
cartilage anlage in the limb bud and of the growth plate arrange in a pattern according to their 
maturation state i.e. resting, proliferating, pre-hypertrophic and hypertrophic, which is mediated 
by a specific spatiotemporal interplay of various signaling factors. It is possible that the absence 
of the spatial component in engineered cartilage could account for the lack of robust 
chondrogenesis by BMSCs. Therefore, we hypothesized that by applying a localized growth 
factor delivery a spatially controlled chondrogenic differentiation of BMSCs can be induced. 
Utilizing the PEG hydrogel system, a versatile tool to immobilize growth factors in a defined way, 
allows to test whether a transplantable growth plate-like structure can be generated from BMSCs 
by recapitulating certain developmental principles (Figure 7A).  Specific goals of thesis part I 
were: 
• Validation of PEG hydrogel as a suitable scaffold for in vitro chondrogenesis. 
• Functionalization of PEG hydrogel with specific growth factors and proving their potential 
to induce the desired chondrogenic phenotype in vitro and in vivo. 
• Combination of differentially functionalized PEG hydrogel layers to generate a bone-
cartilage template in an in vivo ectopic environment. 
 
2.2 Part II: Identification of a BMSC subpopulation with a 
superior chondrogenic differentiation capacity 
Traditionally, BMSCs are isolated from bone marrow containing a mixture of hematopoietic and 
non-hematopoietic cells by their preference to adhere to plastic. This isolation procedure yields 
very heterogeneous cell populations and may account for the high inter-donor variability and 
unpredictability of chondrogenic differentiation out-come in functional assays. Several studies 
have tried to identify surface markers that select more pure BMSCs that enrich for the highest 
CFU-F forming cell population and show tri-lineage differentiation potential within the 
unfractionated bone marrow. Whether there is a sub-fraction of cells within culture expanded 
BMSCs that have a higher and less donor-dependent chondrogenic differentiation capacity has 
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remained elusive. Since single-cell derived clones of fresh bone marrow aspirates show a broad 
range of chondrogenic differentiation, we assessed whether the gene expression profile of 
clones with high and low chondrogenic capacity is different. Second, we anticipated that within 
the differentially expressed genes there are surface markers that potentially could guide to 
prospectively isolate a subpopulation with superior chondrogenic differentiation capacity. 
Ultimately, identification of such a cell fraction and reducing the variance in basic chondrogenic 
differentiation could further aid the process to develop BMSC based cartilage regeneration 
strategies. The specific aims of part II were (Figure 8): 
• RNA sequencing of single cell derived clones with high and low chondrogenic 
differentiation capacity. 
• Prospective isolation and chondrogenic assessment of sorted BMSCs from bulk 
expansion cultures based on specific surface markers identified by the transcriptomic 
analysis. 
 
Figure 8: Experimental set-up of part II. Single cell-derived clones are isolated in order to address i) whether there 
is a correlation between the in vitro chondrogenic capacity of clones and their transcriptome and ii) to identify surface 
marker(s) that could be suited for prospective isolation of multiclonal BMSCs with a higher chondrogenic capacity.  
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3 Results and Discussion 
3.1 Part I - Functionalized hydrogels to engineer in vivo 
osteochondral composites by spatially controlled 
induction of endochondral ossification 
3.1.1 Validation of PEG hydrogel as a suitable scaffold for 
chondrogenesis of BMSCs 
The suitability of the PEG-based hydrogels for in vitro chondrogenic differentiation of BMSCs 
was assessed and compared with scaffold-free pellet cultures. When 0.25x106 BMSCs (the 
same number as used for pellets) were encapsulated in the hydrogel of 10 µL volume, BMSCs 
formed a cartilaginous matrix rich of GAG and collagen type II (ColII) within two weeks of culture 
in chondrogenic medium containing TGFß3 (ChM) similarly to when cultured as pellets (Figure 
9A). Compared to pellet culture the total amount of glycosaminoglycan (GAG) accumulated and 
the DNA content per construct was higher indicating for superior chondrogenesis and higher cell 
survival and/or proliferation (Figure 9B). In this system the presence or absence of the adhesion 
peptide RGD did not influence chondrogenic outcome, as the amount of accumulated GAG per 
construct was very similar with the three different RGD concentrations tested (Figure 9C). To 
test the impact of cell density on chondrogenesis, BMSCs were encapsulated at various cell 
densities from 1.6x to 50x 106 cells/mL of pre-polymerized gel solution. Clearly, the higher cell 
density the more GAG was deposited and below 12x 106 cells/mL chondrogenesis was 
suboptimal (Figure 9D). In order to monitor the degree of hydrogel degradation during 
chondrogenic culture, FITC was covalently incorporated into the hydrogel network. While directly 
after cell encapsulation the green fluorescence showed a homogeneous smooth pattern, with 
increasing culture time fluorescence disappeared directly around the cells and sometimes also in 
small areas indicating that the hydrogel was degraded in close proximity to the cells (Figure 9E). 
In summary, these experiments demonstrated that the here-used PEG system is well compatible 
with chondrogenic differentiation of BMSCs.  
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Figure 9: BMSCs underwent reproducible in vitro chondrogenic differentiation in PEG hydrogels in a cell 
density dependent way. A) 0.25x 106 BMSCs were encapsulated in 10 µL MMP-degradable PEG hydrogel 
containing RGD adhesion peptide or prepared as pellets and cultured for two weeks in ChM. SafraninO/fast green 
(SafO/FG) staining and IF for collagen type II (ColII) of paraffin sections are shown. B) Glycosaminoglycan (GAG) 
accumulation in hydrogels and pellets was quantified by DMMB assay and presented as total GAG normalized to total 
DNA content and as GAG per construct. N=6, 2 replicates each. Paired t-test, P-values = *0.0044, **0.001 C) BMSCs 
were encapsulated in PEG hydrogels containing 0, 25 µM or 50 µM RGD, respectively and cultured for two weeks in 
ChM. GAG and DNA content was quantified. N=3, 2 replicates each. D) GAG and DNA quantification of hydrogel 
constructs generated with various cell densities (1.5x 106 - 50x 106 cells /mL hydrogel) and cultured for two weeks in 
ChM. N=3, 2 replicates each. E) Hydrogel degradation was determined by visualizing enzymatically incorporated FITC 
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to the hydrogel network on cryosections from hydrogels cultured 0, 5 and 14 days in ChM. Green: FITC, blue: DAPI, 
encircled area indicates region with complete absence of FITC, but DAPI positivity indicative for replacement of the 
hydrogel by newly deposited matrix. Scale bars: 500 µm (low) and 200 µm (high magnification). N=1, two replicates 
each time point. 
 
3.1.2 Osseous layer 
3.1.2.1 Functionalization of PEG hydrogel with TGFß3 
Next, aiming at delivering TGFß, the only known factor reliably inducing chondrogenesis of 
BMSCs, in a spatially controlled way we functionalized the PEG-based hydrogel with TGFß3. 
We used the strategy introduced by Metzger et al. [148], in which streptavidin is covalently linked 
to the hydrogel network and biotinylated growth factors are used (Figure 10A). The release of 
biotinylated TGFß3 (bTGFß) samples (Figure 10B) from acellular hydrogels polymerized in 
absence and presence of streptavidin was monitored for one week. Whereas without 
streptavidin almost all of the added bTGFß3 was released, with streptavidin the hydrogels 
retained the majority of the bTGFß3 (Figure 10C). Less bTGFß3 was measured in the 
supernatant with the sample containing no non-biotinylated TGFß3 (bT3.2 in Figure 10B) 
indicating that basically only the non-biotinylated fraction was released from the streptavidin 
containing hydrogels. To test whether chondrogenesis occurs in functionalized hydrogels 0.5, 1 
and 3 ng bTGFß3 /uL (corresponding to totally 5 / 10 / 30 ng of TGFß3 - a similar amount as 
used for the soluble stimulation) was immobilized in the hydrogels. Irrespective of the amount of 
bTGFß3 added to the hydrogel, the chondrogenesis reached similar levels as when delivered 
through the medium (Figure 10D and E). Furthermore, in absence of streptavidin, the single 
TGFß3 pulse was also sufficient to induce chondrogenesis efficiently (Figure 10D and E). In bi-
layered constructs, in which only one part contained bTGFß3, pronounced chondrogenesis 
occurred in the bTGFß3 containing part, while in the other part at the boarder only a limited 
amount of GAG could be detected. Immobilization did not improve the localized differentiation, 
since also in absence of streptavidin, chondrogenic differentiation in the bTGFß3-deficient part 
did not occur in a more pronounced way (Figure 10F).  In summary, neither biotinylation of 
TGFß3, nor its immobilization in the hydrogel compromised its bioactivity to induce chondrogenic 
differentiation of BMSCs, and immobilization proved not to be advantageous over simple 
addition to the hydrogel. 
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Figure 10: Immobilized TGFß3 in the hydrogel induced chondrogenic differentiation of BMSCs to the same 
extent as when delivered soluble. A) Scheme of the functionalization strategy. TGFß3 was immobilized by 
incorporating streptavidin covalently in the hydrogel network and using biotinylated (b)TGFß3. B) bTGFß3 variants 
(bT3.1 and bT3.2) were analyzed by time of flight mass spectrometry to determine the degree of biotinylation per 
dimer. C) bTGFß3 release from acellular hydrogels with and without streptavidin into the supernatant was determined 
by ELISA and normalized to the total amount added to the hydrogel. N=2, 4 replicates each. D-E) BMSCs were 
cultured for two weeks in hydrogels with immobilized or non-immobilized bTGFß3 (bT3.1) at 0.5, 1 and 3 µg/mL and 
soluble bTGFß3 (bT3.1). GAG/DNA was quantified and normalized to the control (bTGFß3 added to the medium). 
Immobilized (blue) and non-immobilized (red) bTGFß3 (D). N=3, 2 replicates each. Representative images of 
SafO/FG staining of cultures with 1 µg/mL (non-)immobilized and soluble TGFß3 are shown (E). F) Bi-layered 
hydrogels composed of a part with immobilized or non-immobilized bTGFß3, cultured in ChM in absence of soluble 
TGFß3. Representative images of SafO/GF staining of paraffin sections are shown. N=3, 1-3 replicates each. Scale 
bars: 200µm.  
 
3.1.2.2 Ectopic implantation of TGFß3-functionalyzed PEG hydrogels 
 
Figure 11: BMSCs in TGFß3-functionalyzed PEG hydrogels efficiently underwent endochondral ossification in 
vivo without an in vitro pre-culture step. A) 20-25x 106 cells/mL BMSCs were encapsulated in hydrogels containing 
immobilized TGFß3 at a concentration of 1 µg/mL hydrogel (corresponding to 10 -20 ng per 10-20 µL hydrogel) and 
were directly implanted subcutaneously in nude mice. Constructs were explanted after 2 (N=2, 2-4 replicates), 4 (N=3, 
2 replicates), 8 (N=7, 2-3 replicates) and 12 weeks (N=8, 2-4 replicates), respectively and paraffin sections were 
analyzed by SafO/FG staining and IF for ColI (human and mouse specific), II, X. Scale bars: 200 µm.  B) Histological 
scoring obtained by valuing the SafO/FG stained sections with a number of 0-3 based on their maturation grade (see 
Table 3). 
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Because TGFß3 is the main inducer of chondrogenesis, we hypothesized that delivering TGFß3 
in the hydrogel is enough to steer endochondral ossification in vivo without the prerequisite in 
vitro pre-culture step. For that purpose, hydrogels containing 1µg/mL immobilized TGFß3 
(corresponding to 10-20 ng TGF ß3 per hydrogel) were implanted subcutaneously in nude mice 
immediately after cell encapsulation. After two to four weeks, chondrogenesis was observed as 
seen by positivity for SafO staining, the rounded cell morphology and the presence of ColII, and 
X (Figure 11A). After four to eight weeks cartilage tissue remodeling to bone was observed, an 
increased area of the tissue was positive for ColI and partially infiltrated by bone marrow. After 
eight to twelve weeks full ossicles developed consisting of a cortical bone rim with typical spindle 
shaped osteocytes enclosing bone marrow (Figure 11A). While the ColI in ECM denser regions 
percolating the ColX positive areas with big rounded cells was of human origin, the more mature 
bone tissue forming the rim of the constructs was exclusively of mouse origin indicating that the 
recruited mouse cells were mainly responsible for bone formation in situ.  
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Figure 12: Ossicle formation in PEG hydrogels with immobilized TGFß3 was more efficient than in non-
functionalized hydrogels after two weeks of in vitro pre-culture in ChM. A) BMSCs were encapsulated in PEG 
hydrogels containing 1µg/mL immobilized TGFß3 (N=7, 2-4 replicates), 1 µg/mL non-immobilized TGFß3 (N=2, 2 
replicates), and without TGFß3 after two weeks culture in ChM (N=3, 4 replicates) or directly implanted (N=3, 2 
replicates) and explanted after eight weeks. SafO/FG stainings of representative replicates of the best and the worst 
replicate per condition are shown. Numbers on the images indicate their histological score. Scale bar: 200 µm. B) 
Histological scoring obtained by valuing the SafO/FG stained sections with a number of 0-3 based on their maturation 
grade (see Table 1). Unpaired t-test, ***P-value ≤0.0001. 
The SafO/FG stained sections were evaluated with a histological score (Figure 11B). While from 
two to eight weeks the constructs were of increased maturation and in the majority of the cases 
after eight weeks full ossicles had developed with marginal remodeling tissue left, there was no 
improvement observed anymore from eight to twelve weeks implantation time (Figure 11B). 
Addition of TGFß3 to the hydrogels without immobilization also induced endochondral 
ossification and the formation of ossicles, however, by trend with lower efficiency compared to 
the immobilized condition (Figure 12A and B). Clearly, the efficiency of ossicle formation of non-
functionalized hydrogels, which were implanted after two weeks in vitro chondrogenic culture 
was significantly lower compared to the immobilized TGFß3 condition (Figure 12A and B). In 
summary, the TGFß3 presented in the hydrogel (either immobilized or non-immobilized) induced 
efficiently endochondral ossification of unprimed BMSCs demonstrating that the in vitro pre-
culture step can be omitted. 
 
3.1.3 Cartilaginous layer 
3.1.3.1 Blocking VEGF by either by utilizing sFLK expressing BMSCs or by 
functionalization of the hydrogel with sFLK. 
Previous results showed that BMSCs stably expressing a soluble variant of mouse VEGFR2 
(sFLK-1) spontaneously formed cartilaginous tissue upon immediate ectopic implantation without 
showing hypertrophic features like ColX [132]. We anticipated to reproduce this finding with 
sFLK-1-functionalized hydrogels instead of genetically modified BMSCs for the cartilaginous 
layer of the osteochondral construct. As a first step, sFLK expressing BMSCs were assessed in 
the hydrogel for their chondrogenic differentiation properties. Transduction of one fresh BMSC 
 56 
donor with retrovirus expressing sFLK-1 and a truncated version of mouse CD8a resulted in an 
efficiency of 45 % (Figure 13A), 40 % lower than observed by Marsano et al. [132].  
 
Figure 13: BMSCs over expressing sFLK did not undergo (spontaneous) stable chondrogenesis upon ectopic 
implantation. A) Flow cytometric analysis of transduced cells stained for mouse CD8a to determine the transduction 
efficiency. B) SafO/FG staining of paraffin sections and GAG/DNA quantification of transduced and control BMSCs 
after two weeks of culture in ChM in PEG hydrogels. C) sFLK-1-expressing cells were encapsulated in hydrogels with 
and without 1µg/mL immobilized bTGFß3 and immediately implanted. SafO/FG staining of cryosections from explants 
after 2, 8 and 12 weeks are shown. N=1, 2 replicates each. D) sFLK-1-expressing cells were seeded in ultrafoam and 
after one day of culture in vitro in CM implanted in nude mice. SafO/FG staining of cryosections from explants after 
four and twelve weeks and IF staining for BSP after twelve weeks are shown. Scale bars: 500 µm (low) and 200 µm 
(high magnification). N=1, 4 replicates each. 
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In expansion conditions the cells secreted 752 +/- 550 ng/106 cells/24 h, the big standard 
deviation originated from the high dependency on the cell density when the supernatant was 
withdrawn. Strangely, in Marsano et al. [132] the average secretion of sFLK-1 was determined 
with 1.37+/- 0.14 ng/106 cells/24 h cells to be 2 magnitudes lower. The transduction procedure 
did not impair the in vitro chondrogenic differentiation potential of the cells (Figure 13B). 0.25x 
106 cells of sFLK-BMSCs were encapsulated in hydrogels with and without immobilized TGFß3. 
The reason for utilizing also the TGFß3-functionalized hydrogels was, that in previous 
experiments with two formerly transduced sFLK-1 expressing donors, no chondrogenesis was 
observed at all. Therefore, it was hypothesized that the TGFß3 could be the trigger for 
differentiation and the secretion of sFLK-1 could still prevent transformation into bone tissue. In 
case of the empty hydrogels, after two weeks no chondrogenic differentiation was observed, 
after eight weeks 1/2 replicates underwent chondrogenic differentiation and finally after twelve 
weeks, both replicates did not show any signs of chondrogenesis, but were calcified similarly to 
the no-TGFß3 controls with naïve cells (Figure 13C). In contrast, in presence of immobilized 
bTGFß3 clearly the cells underwent chondrogenesis after two weeks and one full ossicle was 
formed after eight weeks, while after twelve weeks both replicates were composed of 
cartilaginous matrix. Unfortunately, the type of the cartilage could not be determined (Figure 
13C). As a control to exclude any unexpected effects of the PEG hydrogel, the cells were also 
seeded in ultrafoam following the method of Marsano et al. [132]. After four weeks, in none of 
the four replicates were signs of chondrogenesis observed and after twelve weeks in all four 
replicates GAG positive areas could be found, however, these regions were of hypertrophic 
phenotype since also BSP could be detected and the GAG positive parts were surrounded by 
denser FG positive matrix suggesting that these constructs were in the process of endochondral 
ossification (Figure 13D). In summary, the sFLK-1 expression induced spontaneous 
differentiation to some extent, however, not of a stable cartilage phenotype. It could be due to 
the fact that more than half of the cells did not express sFLK-1 and that the secreted amount of 
sFLK was not sufficient. 
 
Therefore, the remaining cells were sorted according to CD8a expression that resulted in the 
positive population with more than 90 % CD8a+ cells and a negative subset with one quarter of 
the cells still expressing CD8a (Figure 14A). In vitro both populations were chondrogenic (Figure 
14B) and the amount of sFLK determined in the medium was on average five times higher in the 
positive compared to the negative subpopulation (Figure 14C) indicating that the percentage of 
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CD8a+ cells reflected the amount of secreted sFLK-1. Upon eight weeks implantation, positively 
and negatively sorted cells formed fibrocartilage with little SafO positivity and expression of ColII, 
I and X throughout the construct (Figure 14D). There was no obvious difference between the two 
subpopulations visible indicating that the amount of sFLK produced by the cells might not have 
influenced the differentiation outcome and that there must be other reasons for the discrepancy 
to the findings of Marsano et al. [132].  
 
Figure 14: Enriched sFLK over-expressing BMSCs populations did not undergo spontaneous in vivo 
chondrogenesis. A) Flow cytometric analysis of expanded transduced cells that were sorted based on mouse CD8a. 
B) SafO/FG staining of paraffin sections of the CD8a+ and CD8a- cells after 2 weeks culture in PEG hydrogels in 
ChM. C) Secretion of sFLK-1 by the CD8a+ and CD8a- cells during chondrogenic culture measured by ELISA. The 
number in the bracket indicates the time between the two medium changes. Values are the mean of four replicates. 
D) Sorted cell populations were encapsulated in non-functionalized PEG hydrogels and explanted after eight weeks. 
Paraffin sections were analysed by SafO/FG staining and IF staining for ColI (human specific), II and X. Scale bars: 
500 µm (low) and 200 µm (high magnification). 
For hydrogel functionalization, since sFLK-1 is commercially available as FC tagged fusion 
protein, an affinity binding strategy based on covalent incorporation of ZZ-peptide was selected 
[197]. In order to measure the immobilization efficiency of sFLK in the hydrogel, capture and 
release assays were performed with fluorescently labeled protein. There was no difference 
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observed in terms of fluorescence measured in the supernatants withdrawn from hydrogels 
containing ZZ-peptide and from those without in the capture (Figure 15A) and neither in the 
release assay (Figure 15B) indicating that sFLK-FC could not be bound to the ZZ-peptide 
containing hydrogels. Alternatively, the functionalization with bevacizumab/avastin - a 
monoclonal VEGF antibody used in cancer treatment and bearing a FC domain - was tested. 
From hydrogels with ZZ peptide and loaded with 100 ng bevacizumab, after 7 days the 
cumulative release was approximately 35 %, while in absence of ZZ peptide all the loaded 
bevacizumab was released (Figure 15C). This experiment was only conducted once, but clearly 
proposed bevacizumab to be the favorable candidate for generating a VEGF scavenging 
hydrogel. However, considering that the results with the sFLK expressing cells implanted in PEG 
hydrogels were not promising, we decided not to continue with further characterization of the 
bevacizumab-functionalized hydrogels and their potential to induce chondrogenesis of BMSCs.  
 
Figure 15: Dy550 labeled sFLK-1 could not, while labeled bevacizumab could be immobilized by ZZ peptide in 
the PEG hydrogel. A) PEG hydrogels were generated in presence (+ZZ) and absence of ZZ-peptide (-ZZ) and 
immersed in serum-free medium containing 500 ng/mL labeled sFLK-1-FC. At the indicated time points supernatant 
was withdrawn and fluorescence was measured and compared to the condition without hydrogels. B) Hydrogels with 
and without ZZ-peptide were generated in presence of 100 ng labeled sFLK-1-FC-Dy550 and immersed in SFM. 
Medium was changed at the indicated time points and fluorescence was measured and compared to the control 
without hydrogel containing 100 ng of sFLK. C) The same assay as in B) was performed with labeled bevacizumab 
(avastin). N=1, 4 replicates each. 
 
3.1.3.2 Nasal chondrocytes (NCs) 
In contrast to BMSCs, NCs have robust re-differentiation potential and are therefore a suitable 
cell source for the cartilaginous layer of an osteochondral construct. In order to determine the 
best conditions to induce chondrogenesis of NCs in PEG hydrogels, various cell numbers in 
combination with and without RGD, as well as soluble and immobilized bTGFß3 in vitro were 
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tested. Clearly with decreasing cell density the total amount of GAG produced by NCs unrelated 
to the RGD concentration was diminished similarly to with BMSCs. With different RGD 
concentrations, the variance of GAG accumulation was bigger than observed with BMSCs, but 
still there was no significant difference observable (Figure 16A).  
 
Figure 16: Chondrogenesis by NCs in vivo does not necessitate TGFß3. A) 6, 12.5 and 25x 106 NCs were 
encapsulated in hydrogels containing 0, 25 or 50 µM RGD, cultured for two weeks in ChM and GAG and DNA content 
was determined. The blue line represents the average value from culture as pellets with 0.25x 106 cells. SafO/FG 
staining of paraffin sections of a representative hydrogel with 0.25x 106 cells and 25 µM RGD and of a pellet are 
shown. Scale bar: 200 µm. N=1, 3 replicates. B) Hydrogels containing 0.25x 106 cells and 25 µM RGD in absence of 
any growth factor, in presence of immobilized TGFß3 and non-immobilized BMP-2 at 10 µg/mL were directly after cell 
encapsulation implanted subcutaneously and analyzed after eight weeks by SafO/FG and IF staining for ColI (human 
specific), II and X. N=2 for immobilized bTGFß and without TGFß and N=1 for BMP-2, 2 replicates each. C) The in B) 
mentioned constructs were implanted for three weeks and analyzed by qPCR for gene expression of ColI, II, X, 
VEGFA and chondromodulin as shown normalized to GAPDH. As a reference the cells after 2D expansion and in vitro 
constructs cultured in ChM were used. N=2, 2-3 replicates. **P-value: <0.0001. 
For elucidation of the optimal condition for in vivo re-differentiation, hydrogels without a growth 
factor, with immobilized bTGFß and with non-immobilized BMP-2 (see section 3.1.4.3 for the 
reason) were implanted immediately after cell encapsulation. After eight weeks the NCs formed 
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a cartilage tissue rich in GAG and collagen type II and absent of collagen type X without TGFß3 
(Figure 16B). In contrast, the cells in hydrogels with immobilized bTGFß3 seemed to have 
undergone hypertrophic differentiation, since the SafO positive regions were heavily intercalated 
by FG and collagen type I positive areas as well as abundant collagen type X was detected 
(Figure 16B). Furthermore, addition of BMP-2 to single layered hydrogels with NCs did not 
influence their cartilage forming capacity (Figure 16B). These findings hinted that TGFß3 unlike 
in in vitro [85] caused hypertrophic differentiation of NCs. In order to consolidate these results 
and to assess whether immobilized TGFß had an effect on the angiogenic properties of the 
implants, qPCR of early explants (after three weeks) was conducted. Gene expression analysis 
of the various collagens showed that ColI was indeed significantly higher expressed in the 
immobilized TGFß3 condition, by trend ColX was higher compared to the no growth factor and 
the BMP-2, but similarly expressed compared to the in vitro condition and ColII was not 
differentially expressed (Figure 16C). Chondromodulin - a potent anti-angiogenic molecule in 
cartilage [198] - was not differentially expressed  in the no growth factor or BMP-2 versus the 
TGFß3 condition, but generally up-regulated in the in vivo conditions compared to the in vitro 
control group. In addition, there was no difference in vascular endothelial growth factor (VEGF) 
expression observed (Figure 16C) indicating that altered pro-/ anti-angiogenic properties did not 
account for the observed phenotype of NCs in presence of TGFß3. Taken together, the results 
demonstrated that TGFß3 is not needed, but rather detrimental for in vivo chondrogenesis by 
NCs.  
 
3.1.4 Generation of an osteochondral construct by the combination of 
BMSCs with NCs in bi-layered PEG hydrogels 
For the generation of an osteochondral construct directly in vivo we investigated the potential of 
bi-layered hydrogels containing BMSCs undergoing endochondral ossification with NCs 
undergoing spontaneous re-differentiation to form a bone-cartilage composite. Thus, a hydrogel 
disc with TGFß3 containing BMSCs was joined with a non-functionalized hydrogel disc 
containing NCs expressing green fluorescent protein (GFP) for tracking the respective layers 
upon implantation (Figure 18A). After four weeks, strong chondrogenic differentiation in the 
BMSC- and the NC-layer was observed and throughout the constructs ColI and X were 
expressed (Figure 18C).  
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Figure 17: Combination of the TGFß3-functionalized hydrogel containing BMSCs with a non-functionalized 
hydrogel layer containing NCs resulted in the generation of bone tissue adjacent to cartilage with 
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hypertrophic traits. A) 20-25x 106/mL BMSCs were encapsulated in hydrogels containing immobilized bTGFß3, non-
immobilized bTGFß3 and put on an additional layer containing 20-25x 106/mL NCs devoid of bTGFß3, and directly 
implanted subcutaneously in nude mice. B-C) Constructs were explanted after 4, 8 and 12 weeks, respectively and 
paraffin sections were analyzed by SafO/FG staining and IF for ColI (human and mouse specific), II, X (C). The 
number on the SafO/FG stained images indicates the given histological score. The line in the SafO/FG images marks 
the border between the BMSC- and the NC-part (*), based on IF against GFP. Dashed encircled areas were identified 
as stable cartilage. Scale bars: 200 µm. D) Constructs were scored based on SafO/FG and GFP staining. N=3, 2-4 
replicates each time point and donor. 
After eight to twelve weeks SafO positive hypertrophic cartilage was undergoing remodeling in 
the BMSC-part and in some constructs cortical bone developed and a major part was filled with 
a hematopoietic compartment (Figure 18B and C). Similar to the BMSC only constructs, the ColI 
of mature bone surrounding bone marrow was of mouse origin. In the NC part the developed 
cartilage acquired hypertrophic traits as observed by the increased abundance of dense FG and 
collagen type I positive tissue within the GAG rich area and presence of collagen type X (Figure 
18C). A stable cartilage-like phenotype was rarely observed in certain areas of some constructs. 
It was observed in constructs, of which the two discs presumably had been displaced and the 
initial interface between the two cell types was diminished (Figure 18B and C). 
 
Figure 18: Precise localization of GFP positive NCs was difficult to observe. Immunohistochemistry (IHC) 
against GFP in 12 weeks explants shown in Figure 18B and C. ∆ indicate GFP positive cells outside and inside, and # 
GFP-negative cells inside FG/ColI rich areas. Scale bars: 200 µm (low magnification), 50 µm (high magnification). 
The GFP staining facilitated to clearly assign the NC and the BMSC derived hydrogel parts, 
however was not specific enough to indicate, whether there were NCs within the FG and human 
collagen type I rich pre-bone tissue present (Figure 19). With respect of confining an 
 64 
endochondral phenotype to the BMSC layer no difference was observed whether TGFß3 was 
immobilized or not, thus the formation of biphasic tissue consisting of stable cartilage and bone 
was not improved by the immobilization of TGFß3 (Figure 18D i and iii). Immobilization of 
TGFß3 did not improve either the efficiency of bone tissue formation in the BMSC-part (Figure 
18D ii). However, bone formation efficiency was generally lower in the bi-layered constructs than 
in the single-layered configuration. Namely, after eight and twelve weeks > 50 % of the 
constructs did not contain a bone layer that consisted of at least a small area of cortical bone 
and bone marrow (Figure 18D ii). Taken together, TGFß3 triggered endochondral ossification of 
BMSCs in bi-layered hydrogels, but to a lower efficiency than in single-layered hydrogels, while 
NCs formed cartilaginous tissue displaying some hypertrophic traits.  
 
Figure 19: Without TGFß3 in the BMSC-layer, NCs formed hyaline cartilage. BMSCs were encapsulated in a non-
functionalized PEG hydrogel (A), in a hydrogel containing non-immobilized BMP-2 at a concentration of 10µg/mL (B) 
and put on an additional layer containing NCs. A-B) hydrogels were implanted subcutaneously for eight weeks. 
Representative paraffin sections stained by SafO/FG and IHC for ColI (human and mouse specific), II and X are 
shown. The number on the SafO/FG stained images indicates the given histological score. Scale bars: 200 µm. N=1, 
4 replicates.  
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In single-layered hydrogels containing immobilized bTGFß3 NCs acquired a hypertrophic 
phenotype (Figure 16B). Since in bi-layered hydrogels the TGFß was added not to the NC-, but 
to the BMSC-part it could also be that the proximity to the osteogenically differentiation BMSCs 
caused hypertrophic differentiation of the NCs in the bi-layered hydrogels. To differentiate this 
possibility from the TGFß3 as a cause of their hypertrophy, constructs either devoid of TGFß3 or 
containing BMP-2 as an alternative growth factor to induce endochondral ossification of BMSCs 
were fabricated (Figure 20A and B). Clearly, eight weeks after implantation in hydrogels without 
TGFß3 NCs formed cartilage absent of ColI and ColX (Figure 20A). Interestingly, in the BMSC-
layer although only very limited amounts of GAG were detected, there was positivity for ColX 
and II, indicating that the proximity to the NCs may have induced differentiation of BMSCs also 
in absence of TGFß3 (Figure 20A).  Hydrogels containing non-immobilized BMP-2 in the BMSC-
layer developed into constructs with a clear biphasic configuration, in which NCs formed a SafO 
and ColII positive tissue without ColX, while the BMSCs underwent endochondral ossification as 
seen by the presence of a ColX rich matrix adjacent to bone marrow and cortical bone (Figure 
20B). The stable NC-derived cartilage was not in direct contact with the bone, but it was 
separated from the bone by a big area of hypertrophic cartilage from the BMSC part and bone 
marrow. Furthermore, a BMSC derived fibrotic layer marked the interface (Figure 20B). 
Summarizing, these results suggested that the TGFß3 emanating from the BMSC-part induced 
hypertrophic differentiation of NCs, while BMP-2 allowed the development of stable hyaline 
cartilage adjacent to endochondral bone. 
 
3.1.5 Discussion 
The generation of cartilage bone composite tissues that is envisioned to repair osteochondral 
defects is challenged by the localized induction of cell differentiation as well as their proper 
integration [17]. To achieve this, many different approaches have been implemented such as 
separate in vitro pre-culture [183, 187], composite scaffold materials and architectures [188, 196] 
or differential growth factor functionalization [77, 194] utilizing no [77, 194], one [188, 196] or two 
types of cells [183, 187]. So far none of the strategies has proven to be superior to the other in 
terms of the generation of tissue composites resembling the native architecture. Here, we 
demonstrated that TGFß induced endochondral ossification by BMSCs occurred in a localized 
way and concomitantly with spontaneous re-differentiation of NCs in a bi-layered PEG based 
hydrogel. Unexpectedly, the cartilage formed by NCs acquired hypertrophic traits under the 
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influence of TGFß3 from the neighboring layer and replacement of TGFß3 with BMP-2 in the 
BMSC-part allowed the formation of stable cartilage by NCs. 
 
Previous studies demonstrated that covalently immobilized or affinity bound TGFß elicited 
chondrogenesis of encapsulated BMSCs and/or articular chondrocytes in various scaffold 
systems in vitro [153, 163, 164] to a similar or better degree than the soluble control and also in 
vivo within three weeks [165]. Here, immobilization of TGFß3 in the PEG hydrogel induced very 
efficiently chondrogenesis and subsequent bone formation. Compared to non-immobilized 
TGFß3 the bone formation occurred with higher efficiency indicating that a longer exposure to 
TGFß3 may be beneficial. This is in contrast with a previous study, where addition of TGFß-
loaded gelatin microspheres alone to BMSCs sheaths was not sufficient to induce bone 
formation orthotopically to any comparable extent as when additionally BMP-2 was added [182]. 
Thus, future studies involving elucidation of the time period and amount of TGFß required for the 
highest efficacy are warranted to improve scaffold mediated delivery modes, to optimally deploy 
TGFß and to reduce costs and side effects. Current approaches to generate bone tissue through 
endochondral ossification had relied on a lengthy in vitro pre-culture of two to six weeks to 
produce a chondrogenic template prior to implantation [114, 115, 173-177]. Our study 
demonstrated that by delivering a chondroinductive stimulus with the scaffold the in vitro pre-
culture step can be circumvented. From a clinical point of view, optimization of the fabrication 
procedure including the shortening of the in vitro pre-differentiation step and designing effective 
scaffold systems facilitate faster and more efficient generation of grafts. 
 
Mouse and human specific ColI staining revealed that the bone collar was composed solely of 
mouse collagen, while the tissue undergoing remodeling only contained human ColI indicating 
that the (secondary) bone may have been deposited through the vasculature recruited mouse 
osteoprogenitors and the ECM secreted by human cells may have served as a template. In 
native endochondral ossification hypertrophic chondrocytes can transdifferentiate to osteoblasts 
and together with directly differentiated osteoblasts from the perichondrium build up bone [46, 
47]. Various previous studies using different scaffold systems and implantation sites reported 
differential origin of the newly formed bone [115, 174, 180, 182, 199]. Yet it remains to be 
clarified what is the relative impact of the construct size, the scaffold composition, the pre-culture 
step and the implantation site in determining the origin of the final bone derived by endochondral 
ossification. Consequently, in future studies only labeled cells should be utilized in order to 
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determine the temporal sequence of cellular contributions. While for clinical applications the 
origin of the cells does not play a major role as long as the bone formation occurs efficiently, 
however, for humanized bone organ models to study hematological malignancies with patient 
derived cells in vivo [200, 201] it is critical that the bone formed is of human origin. Thus, this 
system at the moment would not be suited as a humanized bone model and research is required 
to find out how to trigger the graft derived cells to generate bone. Furthermore, if indeed the 
recruited cells contribute more to the final bone, systemic or scaffold delivered administration of 
chemokines such as stromal derived factor 1 (SDF-1), platelet derived growth factor BB (PDGF 
BB) or insulin growth factor 1 (IGF-1) may foster stem cell mobilization [202] and could be of 
benefit for translation.  
 
We observed lower efficiency of bone formation in bi-layered hydrogels (independent on the 
immobilization of TGFß3) compared to the single layered immobilized TGFß3 condition. It could 
be related to the decreased surface accessibility and consequently less efficient vascularization 
because one side of the hydrogel disc containing BMSCs was covered by the second disc 
containing NCs. 
 
We showed that NCs under the influence of TGFß3 underwent hypertrophic differentiation, this 
means in case of bi-layered gels by the TGFß3 emanating from the neighboring layer. The main 
reason for TGFß3 immobilization was the refinement of its spatially specific delivery. Intriguingly, 
there was no difference in terms of abundance and distribution of stable and hypertrophic 
cartilage formed between the immobilized and non-immobilized TGFß3 condition suggesting that 
increased leakage of TGFß to the NC-part by the absence of immobilization could not account 
for the cartilage phenotype formed by NCs. Likewise, in in vitro culture assays with bi-layered 
hydrogels chondrogenesis by BMSCs was induced only in the layer with TGFß irrespective of its 
immobilization indicating no leakage to the TGFß devoid layer. Alternatively, the immobilization 
strategy might not have sufficed to confine TGFß3 only to the BMSC-part. Moreover, it could not 
be excluded that due to active remodeling of the BMSC-layer increased MMP activity also 
caused increased cleavage of the MMP sites in the hydrogel, which resulted in higher release of 
the streptavidin-TGFß complex diminishing the effect of immobilization.  
 
 68 
It remains elusive why the NCs under the influence of TGFß3 in the hydrogel differentiated as 
hypertrophic chondrocytes. It has not been described yet that TGFß induces hypertrophic 
differentiation of (nasal) chondrocytes. In contrast to a previous study that showed that NCs 
despite of being hypertrophically primed after in vitro culture in hypertrophic medium reverted 
back to a stable cartilage phenotype upon subcutaneous implantation [203], expression of the 
anti-angiogenic factor chondromodulin that was attributed to be the reason for the phenotypic 
switch in the former study, was not decreased in the TGFß3 compared to the no growth factor 
and the BMP-2 condition. The histological pictures of the NCs under the influence of TGFß 
strongly reminded to those derived from osteoarthritic cartilage. However, it is known from 
murine osteoarthritic models that excessive TGFß along the cartilaginous-osseous junction 
rather induces osteophyte formation  (bony islands within the cartilage evolved through 
endochondral ossification of periosteal cells) than having a direct effect on the hypertrophic like 
phenotype of osteoarthritic chondrocytes [204]. Furthermore, generally TGFß signaling is 
essential in the joints to maintain a stable hyaline cartilage phenotype and to protect articular 
chondrocytes from undergoing hypertrophy [204]. 
 
Previous studies using the subcutaneous model to generate fully differentiated bi-layered tissues 
have been hampered by either incomplete maturation of the osseous tissue and/or hypertrophic 
differentiation of the cartilaginous part due to suboptimal cell source selection, insufficient stimuli 
or insufficient in vivo maturation time [185-189]. By utilization of BMP-2 in the osseous layer 
hyaline cartilage developed next to endochondral bone and is herewith the first study to our 
knowledge convincingly showing newly generated bone next to newly formed cartilage in an 
ectopic environment. Unlike the natural cartilaginous-osseous junction, which consists of a 
relatively thin layer of calcified ColX positive cartilage [2, 205], we observed between the bone 
and the NC derived stable cartilage a large area of BMSC derived hypertrophic cartilage and to 
lesser extent also bone marrow. 
 
It remains to be elucidated how the formation of an interface including calcified cartilage more 
closely resembling the native one can be achieved. Future investigations may i) include the 
optimization of the system such as adjusted growth factor delivery and/or fabrication of the 
hydrogel interface e.g. through differential physicochemical features of the hydrogel in the 
osseous phase at the interface to the cartilage [206] that could serve as foci for bone ECM 
deposition, ii) address whether interface formation can occur in a self-governed way driven by 
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the cross-talk between the adjacent cells with the commitment to form endochondral bone or 
stable cartilage, respectively, and the concomitant tissue development or iii) whether the 
mechanical parameter absent in the ectopic model will be required. To this end, also a study at 
an orthotopic site necessitates to be conducted. 
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3.2 Part II - Identification of a BMSC subpopulation with a 
superior chondrogenic differentiation capacity 
3.2.1 Transcriptomic analysis of single-cell derived clones 
In order to find marker molecules that could select for BMSC with higher chondrogenic capacity 
(CC) we isolated and expanded single cell derived clones (N=5 donors) and correlated their 
gene expression profile with their chondrogenic in vitro differentiation potential (Figure 8). The 
overall clonal efficiency was 23.2 ± 11.5 %. Clones were expanded for 28 ± 2 days, with a mean 
proliferation rate of 0.7 ± 0.1 doublings/day (Figure 21A, 22A). As expected, chondrogenic 
differentiation occurred to a different extent among the clones (Figure 21B-C and Figure 22B-C) 
and the percentage of clones with high chondrogenic capacity (CC), defined based on a Bern 
score ≥ 3.0, ranged from 13 to 50 %, depending on the donor. 14 clones generated from donor 1 
(batch 1) and 20 clones from donors 2-4 (batch 2) were subjected to RNA sequencing. 
 
Differential gene expression analysis (DGA) on all the 14 clones selected for donor 1 (batch 1) 
demonstrated that clones with high and low CC separated in two clusters, with 58 genes 
significantly differentially expressed (adjusted P. value <0.05) (Figure 21D). In order to reduce 
the confounding effect of the different proliferation rates, in an additional analysis only clones 
with a similar proliferation rate (0.67-0.70, 9 out of 14) were taken into account (Figure 21E), 
while outliers in terms of proliferation rate were discarded. Interestingly, the clustering became 
more prominent and the number of significantly differentially expressed genes rose to 1771 
(Figure 21E). This demonstrated that clones with a closer proliferation rate shared more 
common gene expression patterns and that the different doubling times introduced more 
heterogeneity eventually masking the putative similarities among clones with equal CC. Amid the 
significant genes (fold up-regulation > 12 in clones with high CC), there were extracellular matrix 
proteins, which are important components of the cartilage ECM such as hyaluronan and 
proteoglycan link protein (HAPLN1), aggrecan (ACAN) and cartilage oligomeric matrix protein 
(COMP) (Figure 21F). Moreover, several surface markers (NCAM1/CD56, VACAM1/CD106, 
ALCAM/CD166, ITGA1/CD49a) were significantly higher and two were significantly lower 
expressed (ENG/CD105 and CSF1R/CD115) in the clones with high CC, with CD56 having the 
highest fold change (Figure 21F).  
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Figure 20: Gene expression and chondrogenic capacity correlated and was more pronounced if proliferation 
outlier clones were excluded. A) Proliferation rate of single cell derived clones. B-C) Clones were cultured as pellets 
(1-2 replicates) in chondrogenic medium (ChM) for three weeks and assessed histologically. Bern score was used to 
evaluate the SafO/FG stained sections (B). Scale bar: 200 µm. Bern scores: c35: 8.5, c50: 3.25, c19: 6.25, c12: 3.0, 
c49: 9, c44: 0, c16: 0, c17: 0, c28: 0, c9: 8, c22: 1, c26: 0.5, c34: 0, c48: 1.5. Clones with a Bern score ≥ 3 (red 
dashed line) were assigned to have a high CC. D) Differential gene expression analysis (DGA) comparing clones with 
low and high CC. E) DGA of clones with a similar proliferation rate (c35-c28). F) Heatmap of surface markers (*ROR2 
was not on the list from the DGA, but was identified by a previous study [207]), cartilage ECM proteins and genes 
associated with chondrogenic differentiation identified by ingenuity pathway analysis (IPA) that were among the 
significant genes of the subset analysis of batch 1. G) Gene expression of NCAM1 in clones analyzed by qPCR and 
normalized to GAPDH. Unpaired t-test, *P-value = 0.04. H) Differentially expressed genes involved in canonical 
signaling pathways as determined by IPA. Bar height indicates P-value as calculated by Fisher's exact test right-tailed 
that is indicative for the probability of association of the data set and the pathway.  
The significant up-regulation of CD56 in clones with high CC was also confirmed by qPCR 
(Figure 21G). Ingenuity pathway analysis (IPA) showed that downstream targets of PDGFBB 
signaling were down-regulated, targets of TGFß signaling were down- and upregulated to equal 
degrees in clones of high CC, and that genes implicated in chondrogenesis were rather 
increased (Figure 21F). Among the pathways with the highest coverage of differentially 
expressed genes there were EIF2, estrogen, mTOR, eIF4, and IL8 signaling pathways, the first 
presumably being deactivated and the latter three activated in clones with high CC (Figure 21H). 
 
Clones from three additional donors were combined and subjected to RNA sequencing (batch 2) 
(Figure 22) that was performed in order to validate the discovered genes in batch 1 to be related 
to the CC in a less donor dependent manner. Principle component analysis (PCA) showed that 
all clones grouped according to the donor origin, clones from the batch 2 were furthest apart 
from the clones of batch 1 (Figure 22D). Since the number of samples per donor was low, the 
differential gene expression analysis was done for all the clones irrespective of their proliferation 
rate. The big dissimilarity of the clones from different donors suggested that the donor-to-donor 
variability is bigger than the clone of high CC to low CC variability. This was confirmed by DGA, 
which yielded six significantly differentially expressed genes (Figure 22E). None of these six 
genes overlapped with the genes found in batch 1 (independent whether all clones or the subset 
with similar proliferation rate was taken into account). Plotting the counted reads of CD56 
mRNAs, it was visible that there was a trend of higher expression in clones with high CC (Figure 
22F). This trend was confirmed by qPCR analysis and again the variability was too high and 
therefore did not reach significance (Figure 22F). Furthermore, clonal populations were also 
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assessed by flow cytometry for CD56, the trend of a higher frequency of CD56+ cells among the 
clones with higher CC was also here apparent, but not significant (Figure 22G). Taken together, 
NCAM1/CD56, VACAM1/CD106, ALCAM/CD166, ITGA1/CD49a were identified by RNA 
sequencing as putative markers for clones with high CC. However, donor-to-donor variability 
masked the confirmation of these surface markers to be significantly up-regulated in clones of 
high CC from various donors and masked the identification of further putative marker genes. 
 
Figure 21: Transcriptomic analysis of clones from other three donors did not confirm the data of the first 
batch. A) Proliferation rate of clones. B) Bern score of clones after three weeks in culture in ChM. Clones with a Bern 
score ≥3 (red dashed line) were considered as clones with high CC. C) SafO/FG staining of paraffin sections. 1-2 
replicates per clone. Scale bar: 200 µm. D) Principal component analysis (PCA) comparing clones of all tested 
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different donors (batch 1 and 2). B) Significantly differentially expressed genes of batch 2 (adjusted p value < 0.05). 
C) NCAM1 expression by counted reads from the RNA sequencing (upper graph) and by qPCR in batch 2 clones. G) 
Clonal populations of donor 2 and 3 were assessed by flow cytometry before subjection to the chondrogenic culture 
for the frequency of CD56+ cells. 
 
3.2.2 Sorting of expanded multiclonal BMSCs based on CD56/NCAM1 
Aiming at finding surface marker(s) that select for BMSCs with higher CC within the bulk, 
expanded multiclonal BMSCs (P1) were analyzed for the surface markers found to be up-
regulated in clones with high CC in batch 1. CD49a, CD105 and CD166 were expressed in all of 
the cells, while on average 93.9 +/- 7.1 % of the cells were positive for CD106 (N=7 donors) and 
the frequency of CD56+ cells ranged between 1 and 35% with an average of 13 +/- 11% CD56+ 
cells (N=12 donors) (Figure 23). Previously it was reported that cultured unfractionated BMSCs 
(passage 2) were 100% positive for CD166, while for CD106 two populations remained [208] 
and the frequency of cells positive for CD56 in P2-P3 cells was determined between 24-89% 
[209]. Markers exhibiting high and stable expression profiles are unlikely to be unique markers of 
BMSCs with high chondrogenic potential. Instead markers with low expression, reflecting the low 
presence of chondrogenic clones in the total BMSCs population are more likely to be unique 
markers of chondrogenic BMSCs [210]. Therefore, we pursued CD56 for comparative studies of 
CC. 
 
Figure 22: CD56+ cells as determined by flow cytometry in multiclonal populations at P1 were present to 
different extents among donors. Three donors representing the range of CD56+ cell frequencies are displayed 
(N=23).  
CD56 or NCAM1 (neural cell adhesion molecule) originally discovered in neurons is a 
immunoglobulin-like domain containing transmembrane glycoprotein engaged in homophilic cell-
cell contact and heterophilic cell-ECM adhesion and is expressed in adult organisms by various 
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tissue cells [211]. It is expressed on uncultured [208] and cultured adult human BMSCs [209] 
and in-situ CD56 was detected rather to be co-expressed on CD271+ bone-lining MSCs than at 
perivascular location [212]. Experiments in vivo and in vitro with chicken limb bud progenitor 
cells demonstrated that NCAM by mediating cell condensation at the onset of chondrogenic 
differentiation is important for the quality of the chondrogenesis [213, 214]. The functional 
implication of CD56 during chondrogenesis further motivated us to determine the chondrogenic 
potential of CD56+ cells.  
 
Figure 23: Enriching for CD56+ cells resulted in a trend of higher chondrogenesis. A) Representative FACS plot 
of CD56 stained P1 cells. The squares indicate the populations, which were sorted as CD56+ and CD56-. B) Gene 
expression of CD56 normalized to GAPDH directly after sorting (N=3) and after expansion (N=5). Paired t-test, *P-
value = 0.04 C-E) Sorted populations and as a control the unsorted ones were cultured for two weeks in ChM as 
pellets and in PEG hydrogels. N=2, 1-2 replicates each culture condition and cell subset. SafO/FG staining of paraffin 
sections of donor 5 are shown. Scale bar: 200 µm (C). Semi-quantification of SafO/FG stained sections by Bern score 
(D) and quantification of accumulated GAG/DNA represented for every donor and culture system separately. Paired t-
test, **P value = 0.00017, *P value = < 0.05 (E). F-G) In vitro cultured hydrogels were subcutaneously implanted in 
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immunocompromised mice. SafO/FG staining, representative replicates of donor 5 are shown (F) and histological 
score (G). N=2, 2-4 replicates each cell subset. Scale bar: 200 µm. Paired t-test, **P value= 0.001. 
To verify the potential of CD56 to select for BMSCs with high CC, P1 expanded BMSCs were 
sorted (Figure 24A) and CD56 positive and negative sub-populations were tested in 
chondrogenic cultures, using unsorted BMSCs as a control (Figure 24C-E). The gene 
expression levels of CD56 directly after sorting and after expansion were more than one order of 
magnitude higher in the CD56+ cells as compared to the negative ones and the unsorted cells 
showed an intermediate expression level (Figure 24B). This demonstrated that the sorted 
populations clearly differed in terms of CD56 mRNA amounts. Interestingly, the expression 
levels were slightly lower after expansion in all cell populations (Figure 24B). Two donors could 
be assessed in terms of chondrogenic potential in two separate experiments as pellet and PEG 
based hydrogel cultures. For both donors for all cell populations the chondrogenesis took place 
to a very limited extent as pellet cultures and at an intermediate to good level in the PEG 
hydrogels. There was a trend that chondrogenesis of CD56+ cells was better compared to the 
negative and the bulk (Figure 24C-E), however, as measured by GAG quantification it was 
significantly better only in case of donor 5 when cultured as pellets and in case of donor 6 when 
cultured in hydrogels, but there the difference was only visible between positively and negatively 
sorted populations (Figure 24E). These observations were also reflected in the histological 
analysis (Figure 24D). Because sole enrichment of a BMSC population with higher CC (without 
adaptation of the differentiation conditions) is very unlikely to decrease the inherent tendency of 
BMSCs to form (pre-)hypertrophic chondrocytes, we implanted the in vitro cultured hydrogels 
subcutaneously to assess their bone formation potential. After eight weeks, there was no 
difference between positively and negatively sorted cells (Figure 24F-G). Interestingly, the 
negative cells developed significantly more into mature ossicles than the bulk cells (Figure 24G).   
 
 
Figure 24: Relatively low proliferation rate of multiclonal 
BMSCs irrespective of sorting. The proliferation rate was 
calculated by using the plated cell number and the total number 
of cells counted at the end of the expansion phase. In general, 
cells were expanded on average for 8 days. N=15. 
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In summary, despite of the trend of better chondrogenesis by CD56+ compared to the CD56- 
cells, due to the donor and also the intra-replicate variability it was not possible to draw a 
conclusion whether enrichment for CD56 could improve the BMSCs chondrogenic differentiation 
capacity. It would be mandatory to assess more technical replicates and more donors, however, 
a big problem encountered was that these donors did not proliferate sufficiently and it was often 
not possible to retrieve enough cells. With average proliferation rates of 0.30 +/- 0.18 for the 
positive, 0.29 +/- 0.18 for the negative and 0.42 +/- 0.22 doublings/day for the unsorted 
populations, respectively, they proliferated 2-3 times lower than usually observed with BMSCs at 
P0-3. Comparing to the proliferation rate of unsorted cells the FACS process did not seem to be 
the cause for the slow proliferation, even though the sorted cells proliferated a bit less (Figure 
25). 
 
In order to better characterize the heterogeneity within the CD56 sorted cell populations, single 
cells from P1-expanded BMSCs sorted based on CD56 were collected and expanded (Figure 
26A). 10.4 % of the CD56+ and 5.9 % of the CD56- derived clones with appreciable proliferation 
rates were retrieved. Clones were expanded for on average 24.15 ± 2.66 and 22.93 ± 3.63 days 
and showed a mean proliferation rate of 0.81 ± 0.11 and 0.86 ± 0.14 doublings/day, respectively 
(Figure 26B). The gene expression of CD56 at the end of the expansion phase was inconsistent 
with the clone origin - derivation from CD56+ or CD56- sorted single cell – and it did not correlate 
with the CC of the underlying clone (Figure 26C). After expansion clones were subjected to in 
vitro tri-lineage differentiation assays. Regarding chondrogenic potential, 1 clone out of 11 and 4 
clones out of 22 showed high CC within the CD56- and CD56+derived clones, respectively, not 
resulting in a significant difference between the two subpopulation derived clones (Figure 26D). 
The CD56+ clones were marginally osteogenic and adipogenic, while with the exception of one 
clone all CD56- clones were osteogenic (Figure 26E) and the majority underwent adipogenesis 
(Figure 26F), as measured by alizarin red staining for calcification and oil red staining for the 
accumulation of fat droplets, respectively. In conclusion, the big discrepancy in osteogenic and 
adipogenic differentiation potential suggested that the CD56+ and CD56- are indeed two distinct 
cell populations. 
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Figure 25: CD56+ and CD56- single cell derived clones differed clearly in terms of adipogenic and osteogenic, 
but not chondrogenic differentiation potential. A) P1-expanded BMSCs were single cell sorted based on CD56 
protein expression. B) Proliferation rate of CD56 positive and negative clones. C) Gene expression by qPCR of CD56 
normalized to GAPDH after expansion. D) Clones were cultured for three weeks in ChM. SafO/FG staining of paraffin 
sections are shown and the CC was evaluated by using the Bern score. E) Adipogenic differentiation for three weeks. 
Staining for oil red and quantification by counting the cells clearly containing lipid droplets. F) Osteogenic 
differentiation for three weeks. Staining for alizarin red and colorimetric quantification thereof. Unpaired t-test, P value 
= ***0.0009, ****<0.0001. The gray line corresponds to the average value measured by P3 unsorted cells. Because 
often there was no single clone representative for all clones within one population, the best, intermediate and worst 
clone are presented from left to right. Scale bars: 200 µm.  
 
3.2.3 Discussion 
BMSCs are considered as promising therapeutic candidate for cell-based articular cartilage 
repair and regeneration strategies. However, their application in the routine clinical practice is 
hampered by their large inter- and intra-donor variability in terms of proliferative and 
(chondrogenic) differentiation potential [116, 210]. In this study, we explored the existence of 
predictive markers identifying BMSCs subsets with high chondrogenic capacity (CC), starting 
from analyzing the molecular signature of clones with differential CC derived from single 
BMSCs. Transcriptomic data from one donor gave a clear cut difference between clones with 
high and low CC and hinted NCAM/CD56 as a marker to prospectively isolate a subpopulation of 
BMSCs with superior chondrogenic potential. BMSCs’ donor-to-donor variability still remained 
the main obstacle impeding the possibility to draw final conclusions on the applicability of 
exploiting transcriptomic data from a very small number of donors and of the translational 
potential of CD56 as a selection marker. 
 
Aiming to overcome the heterogeneity of bulk BMSCs isolated from bone marrow aspirates we 
investigated whether gene expression correlates with the CC of individual single BMSC-derived 
clones. Differential gene expression analysis resulted in the segregation of clones with high and 
low CC indicating a correlation between the gene expression profile and the CC of the 
underlying clone. Surprisingly, the segregation of the two groups was even more prominent 
when clones with a different proliferation rate than the average (proliferation outliers) were 
excluded from the analysis. These results suggested that differences in proliferation of individual 
clones might have introduced randomization of the gene expression profile according to 
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chondrogenic capacity. Additional clones from three different donors were subjected to RNA 
sequencing (batch 2) in order to assess, whether the results obtained by the transcriptomic 
analysis of batch 1 are donor-independent. The segregation of clones with high and low CC was 
poor and the results from batch 2 could not corroborate the findings from the first one. Of note, 
in batch 2 it was not possible to exclude proliferation outliers due to the low number of clones 
available from each donor. Overall, our analysis suggested that donor-to-donor variability 
exceeded the gene expression difference based on CC, masking the putative similarities among 
clones with similar chondrogenic potential. It could not be excluded that variable culture 
conditions such as the duration of expansion or different cellular confluence states at the time of 
harvest introduced additional variance. The difficulty in extrapolating predictive markers from 
differential gene expression analysis between single BMSC- derived clones was reported 
previously with a bovine bone marrow donor [199]. Our results highlighted the requirement for a 
more comprehensive analysis, considering a significant higher number of donors and clones per 
donor, what stands in contrast to the study of Dickinson et al [207].  
 
Interestingly, when excluding the proliferation rate as a confounding effect in the analysis of 
batch 1, three cartilage ECM proteins (HAPLN1, COMP and ACAN), and most importantly 
several surface markers were found to be significantly up-regulated in clones with high CC. 
Among them, NCAM1/CD56 was the surface marker with the highest fold change difference 
between clones with high and low CC. Moreover, CD56+ cells were present at varying low to 
intermediate frequencies in different donors of heterogeneous BMSC populations. Together with 
N-cadherin, CD56 has previously been demonstrated to be an important mediator for cell-cell 
adhesion during pre-chondrogenic condensation of chondroprogenitors in limb bud development 
[213-215]. Because the initial condensation phase is also critical for triggering in vitro 
chondrogenesis of adult BMSCs [216-218], enrichment of cells with high CD56 expression might 
be beneficial. CD56+ sorted cells from expanded multiclonal BMSCs did not exhibit 
unequivocally a higher chondrogenic potential compared to the bulk or the CD56- cells, although 
a trend along this line was visible. The non-significance was attributed mainly to the low tested 
donor number and technical replicates due to low proliferation rates of the (sorted) cells.  
 
To further investigate the heterogeneity within the CD56 sorted cell populations, single CD56+/- 
cell-derived clones were compared in tri-lineage differentiation assays. A clear distinction 
between the two subpopulations was evident in terms of osteogenic and adipogenic 
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differentiation capacity (good in CD56- clones and absent in CD56+ ones), while the difference in 
chondrogenesis was less conclusive. Previously, Battula et al. sorted CD56+ MSCs from CD45 
depleted human bone marrow in combination with MSCA-1 and CD271. Interestingly, the 
authors observed higher CFU-Fs and better chondrogenic in vitro differentiation compared to the 
CD271+MSCA-1+CD56- cells and better adipogenic differentiation of CD56- cells at multiclonal 
and clonal level [102]. Since our results overlapped with this precedent study, although different 
sorting times were applied (post- versus pre-expansion), it may indicate that CD56 expression 
identifies a certain cell subpopulation not only in naïve BMSCs, but also in expanded cells, what 
would underline the relevance of CD56+ as a prospective marker. Moreover, the non-significant 
difference of in vitro chondrogenesis between the CD56+ and CD56- cell subsets does not 
exclude a potential more significant difference at an in vivo orthotopic site [207]. A very recent 
report identified ROR2 (a Wnt receptor) as a putative marker for cells with increased CC by 
transcriptomic comparison of clones with differing CC from one human bone marrow donor. The 
expression of ROR2 in cultured BMSCs was induced by high cell density expansion to varying 
degrees. The positively sorted cells showed increased chondrogenic potential in vitro and in a 
sheep full thickness cartilage defect; the differences being more pronounced in vivo than in vitro 
[207]. In our transcriptomic data ROR2 was detected at low levels and was not differentially 
expressed in clones with high and low CC, conversely CD56 was not part of the data set of 
Dickinson et al. [207]. The cell density at the time of the RNA harvest could account for the 
discrepancy between our and their results. Nevertheless, it would be interesting to elucidate the 
relationship of CD56+ and ROR2+ cells after expansion. 
 
From a translational point of view, the most important criteria for the applicability of a selection 
strategy is the cell yield that can be achieved with it. The decision to analyze and sort expanded 
and not freshly isolated or minimally expanded cells could have been a caveat of this study. 
Surface marker expression is known to be affected by in vitro culture conditions and most 
probably does not correspond any more to that of certain naïve subpopulations [90, 208, 219]. 
Therefore, analysis of cell-subpopulations cultured for a minimal time just to retrieve enough 
material for bulk RNA analysis and comparing them to the in vitro and in vivo differentiation 
potential of their counterparts expanded for longer times, eventually combined with index sorting 
to generate single cell derived clones instead of simple manual seeding, as well as single cell 
RNA sequencing could be more successful in finding the markers for a true chondroprogenitor 
population within human bone marrow and could uncover if at all it is existing.  
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4 Conclusions 
By exploiting the cell intrinsic propensities of bone marrow derived mesenchymal stromal cells 
and nasal chondrocytes, in combination with the cell-degradable PEG based hydrogel system 
this study demonstrated that without the need of a prolonged in vitro-pre-differentiation step a 
cartilage-bone composite could be generated at an ectopic site. The PEG hydrogel provided for 
both tissues an ideal environment to evolve and allowed for localized growth factor 
functionalization. Specifically, delivering TGFß3 in an immobilized fashion in the PEG hydrogel 
induced formation of faithful bone organoids by BMSCs directly in vivo. In bi-layered gels, we 
observed that the TGFß3 emanating from the BMSC-layer triggered NCs to acquire hypertrophic 
traits. Utilization of BMP-2 instead of TGFß3 allowed the formation of stable cartilage next to 
endochondral bone demonstrating unequivocally the ability of the here-used system for the 
generation of osteochondral composites. A future study in an orthotopic animal model will be 
needed to unearth the potential clinical relevance of these bi-layered hydrogels containing 
BMSCs and NCs in the context of osteochondral repair.  
  
Given that single cell derived clones generated from one bone marrow donor show differential 
chondrogenic differentiation capacity highlighting the cell heterogeneity within cultured BMSCs, 
our study compared the transcriptional profile of clones with high and low chondrogenic capacity 
in order to find selective markers for prospective isolation of a cell subset with superior 
chondrogenic potential within the bulk BMSCs. Differential gene expression analysis resulted in 
a segregation of clones with differential chondrogenic capacity and proposed NCAM1/CD56 to 
be such a selective marker. By trend, from multiclonal BMSCs sorted CD56+ cells displayed a 
higher chondrogenesis than the CD56- cells, however, analysis of more donors are needed in 
order to confirm these data. Further RNA sequencing of clones from other donors resulted in a 
very poor clustering indicating the importance to analyze a very high number of donors and 
clones for reliable marker identification. Moreover, to exclude confounding effects of extensive 
expansion and varying culture conditions it would be important to analyze the transcriptome and 
prospectively sort BMSCs at a very early time point, while performing functional assays on their 
expanded progeny.  
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5 Materials and methods 
If not otherwise stated all reagents were purchased from Sigma. Cell culture media and 
supplements are from Gibco. 
Cell isolation and expansion  
Bone marrow aspirates and cartilage tissue biopsies were obtained from patients after informed 
consent during surgical procedures in accordance with the local ethical committee (University 
Hospital Basel; Prof. Dr. Kummer; approval date 26/03/2007 Ref Number 78/07). Human 
mesenchymal stromal cells were isolated from bone marrow aspirates (n=23; mean age: 33.7 ± 
10 years, part I and n=11; mean age: 40 ± 13 years, 8:3 male: female for part II) by plating 0.1-
0.13x106 of nucleated cells/cm2 in alpha-MEM with 10 % FBS, 100 mM HEPES buffer, 1mM 
sodium pyruvate, 100 IU/mL penicillin, 100 µg/mL streptomycin and 0.29 mg/mL glutamate, 
supplemented with 5 ng/mL FGF2 (BioTechne) (complete medium, CM) and expanded in the 
same medium for one to two passages more before using them for chondrogenic and 
endochondral assays or expanding them for one passage more for sorting experiments.   
Nasal chondrocytes were isolated from minced nasal cartilage septum biopsies, taken from 
three donors (female, 26; male, 52; male, 41) by digestion in 0.15 % type II collagenase 
(Worthington) for 22 hours at 37˚C. NCs were expanded in DMEM, 4.5 g/L glucose, with 10 % 
FBS, 100 mM HEPES buffer, 1mM sodium pyruvate, 100 IU/mL penicillin, 100 µg/mL 
streptomycin and 0.29 mg/mL glutamate, supplemented with 1 ng/mL TGFß1 (BioTechne) and 5 
ng/mL FGF2 (BioTechne). 
 
Generation of single-cell derived clones 
1x104 nucleated cells from five fresh bone marrow aspirates (23 years, male; 38 years, male; 49 
years, female; 30 years, female; 38 years, male) were seeded in 96 well plates. It is expected 
that the frequency of clonogenic cells is approximately 1/104. After one week the wells were 
checked for colony growth, wells without cells and wells where it seemed that two or more cells 
gave rise to a colony were discarded. Clones were expanded in CM and when a high enough 
cell number was reached (minimum 0.8x106 cells) they were subjected to RNA isolation for 
transcriptomic analysis, chondrogenic assays and flow cytometry in case of donor 2 and 3. If a 
clone stopped growing or showed morphological signs of senescence, it was discarded.  
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For the clonal study of CD56+ and CD56- one P1-expanded donor (age: 33 years, male) was 
sorted based on CD56 expression and single cells were put into 6x 96 well plates and 
processed as described above. The CD56+ cells gave rise to so many clones that after 20 days 
the clones, which were not confluent that time, were discarded. After expansion the clones were 
tested in tri-lineage in vitro differentiation assays. 
 
Lentiviral transduction for GFP 
Lentivirus with GFP was produced as described in Miot et al. [220] by co-transfection of 12 µg of 
pWPXL-EGFP, 12 µg of pCMV∆R8.91 and 5 µg of pMD.2G in 2.5x 106 293T cells using Fugene 
6 (Roche) in DMEM, 10 % FBS, 100 U/mL penicillin and 100 µg/mL streptomycin (CMT). After 
two and three days the supernatant was collected and filtered through 0.45 µm pore size filters. 
For transduction of NCs, passage 2 cells were seeded at a density of 5100 cells/cm2 24 hours 
prior to virus addition. Transduction was facilitated with 2µg/mL polybren. 3 days after 
transduction the cells were analysed by flow cytometry (with accuri, BD) for expression of GFP 
and the percentage of transduced cells was determined in FlowJow.  
 
Retroviral transduction of BMSCs with sFLK-1 
For the generation of the retroviral vector containing mouse extracellular domain of VEGFR2 
(sFLK-1) fused to a IgG2 derived FC domain and linked through an internal ribosomal entry site 
to a truncated version of mouse CD8a, phoenix cells (kept in CM at 32˚C) were transfected with 
the respective plasmids using Fugene 6 (Roche). The supernatant was harvested two times on 
day two, day three and four, and filtered through a 0.45 µm pore size filter. One fresh bone 
marrow aspirate (50, female) was cultured for 6 days at an initial density of 105 nucleated cells 
before transduction. The BMSCs were transduced with the filtered supernatant six times during 
three days with polybrene. The transduction efficiency was determined by flow cytometric 
analysis for mouse CD8 and secretion of sFLK was determined by culturing BMSCs in 60-mm 
dishes for 4 hours in 1 mL CM. After filtration through 0.45 µm pore size filters sFLK in 
supernatants was quantified with the ELISA DuoSet® immunoassay kit (R&D systems) 
according to the user’s manual. sFLK transduced cells and the corresponding non transduced 
control cells were subjected to chondrogenic in vitro and in vivo assays at passage 3.  
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Chondrogenic differentiation 
For chondrogenic pellet cultures, 0.25 M cells were centrifuged for 5 minutes at 1000 rpm in 0.25 
mL serum-free medium consisting of DMEM, 4.5 g/mL glucose with 100 mM HEPES buffer, 
1mM sodium pyruvate, 100 IU/mL penicillin, 100 µg/mL streptomycin and 0.29 mg/mL 
glutamate, 1.25 µg/mL human serum albumin (HSA), insulin-transferrin-selen (Gibco), linoleic 
acid, supplemented with 0.1 mM ascorbic acid 2-phosphate, 10-7 dexamethasone and 10 ng /mL 
TGFß3 (Novartis) (ChM). Pellets were cultured for two weeks if not otherwise stated and the 
medium was changed twice a week.  
 
Adipogenic differentiation 
4x104 of cells were seeded into 12 well plates (1-3 replicates depending on the available cell 
number) and cultured for 2 weeks in adipogenic differentiation medium containing CM based on 
DMEM, 4.5g/L glucose supplemented with 10 ug/mL methyl-iso buthyl xanthine, 10 ug/mL 
insulin Actrapid HM, 0.1 mM indomethacin and 10-4 M dexamethasone and for one week in CM 
containing insulin. After the culture the cells were fixed for 10 min in formalin and stained with oil 
red. For semi-quantitative analysis, three pictures per well were taken with a 20x objective and 
cells clearly showing oil droplet accumulation were counted.  
 
Osteogenic differentiation 
4x104 of cells were seeded into 12 well plates (1-3 replicates depending on the available cell 
number) and cultured for 3 weeks in osteogenic differentiation medium containing CM based on 
alpha-MEM supplemented with 0.1 mM ascorbic acids, beta-glycero-phosphate and 10-6 
dexamethasone. Afterwards the cells were fixed for 10 min in formalin and stained with alizarin 
red. For quantitation purposes, after image acquisition the alizarin red was solubilized by 
incubation in 10 % acetic acid at room temperature and at 85 °C, and the with 10 % ammonium 
hydroxide neutralized supernatants were optically measured at a wavelength of 405. 
 
Fabrication of PEG hydrogels 
PEG hydrogels were generated as previously described [146, 221]. Briefly, an equimolar ratio of 
8-armed PEG equipped with peptides that allow for cross-linkage by transglutaminase factor XIII 
and cell mediated degradation (PEG-MMPsensitive-Lys and PEG-Gln) at a concentration for 1.5% 
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w/v hydrogels was polymerized by addition of 10 U/mL of factor XIII in 50 mM Tris buffer, pH7.6 
in presence of 50 mM CaCl2, and 25 µM RGD-Lys, 1 ng/µL bTGFß3, 10 ng/µL BMP-2 and/or 
100 µM streptavidin-Gln as specified in the text. 0.2-0.25x106 cells/1mL were encapsulated if not 
otherwise stated. Single-layered hydrogel discs of 10 or 20 µL were formed sandwiched 
between hydrophobically coated (SigmaCote) glass slides with 1 mm spacers for 30 min at 
37˚C.  The metallic head was used for locally inhibiting the polymerization of the hydrogel using 
electrochemical methods [222], resulting in a thin layer of non-polymerised hydrogel in the 
vicinity of the metallic head, insuring the easy and reproducible detachment of the head. The so-
produced first hydrogel disc was then put on top of a 15-µL drop of hydrogel mix forming the 
second layer. Polymerization and disc combination was allowed for 20 minutes at 37˚C in the 
sandwich of two hydrophobically coated glass slides with a spacer of 2.8 mm. Hydrogels were 
cultured in ChM containing TGFß3 and in case of TGFß functionalization in ChM without TGFß 
supplementation for two weeks with a medium change twice - trice a week, or kept in serum-free 
medium without supplements until implanted subcutaneously (< 4 hours). For the formation of 
biphasic hydrogels side-by side, the first hydrogel disc (25 µL) was polymerized for 5- 10 
minutes in one half of a PDMS mold of 8 x 2 mm in dimension placed on the hydrophobic glass 
slide and the other part (25 µL) was added in the second half and gelation was completed for 20 
minutes at 37˚C.  Hydrogels were either cultured in ChM for 2 weeks with a medium change 2-3 
times/weeks, or kept in serum-free medium without supplements until implanted subcutaneously 
(< 4 hours). When bTGFß3 was added to the hydrogel TGFß3 was omitted in the medium. 
 
Biotinylation of TGFß3: 
Dimeric TGFß3 (Novartis) was biotinylated in 6 M urea, 20 mM HEPES buffer at pH 7 or 8, 
respectively, on ice for 60 minutes using EZ- Link NHS-PEG4-biotin reagent (Thermo Scientific) 
at a 10 or 20 fold molar excess over the protein dimer concentration as stated in the text. The 
reaction was stopped by addition of 1 M Tris buffer, pH 7.6 to a final concentration of 20 mM. For 
removal of unreacted biotin reagent the TGFß3 was dialyzed in ZelluTrans, 3500 MWCO 
(ROTH) into fresh urea buffer for 24 hours at 4˚C. The degree of biotinylation was checked by 
time of flight mass spectrometry performed by the functional genomic center Zürich. 
 
Acellular release assay and ELISA quantification of TGFß3 
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20 µL hydrogels were formed in absence or presence of 100 µM streptavidin-Gln and with 20 ng 
of bTGFß3 in eppendorf tubes, after 30 minutes covered with 500 µL serum-free medium and 
incubated at 37˚C for 7 days. At indicated time points the medium was replaced with fresh one. 
The amount of released bTGFß3 was measured by ELISA (DuoSet, human TGFß3, R&D 
systems) following the manufacturer’s protocol and normalized to the control medium, to which 
20 ng of bTGFß3 was directly added.  
 
Acellular capture and relase assay with sFLK-1 and bevacizumab 
Recombinant sFLK-1-FC (R&D systems) or bevacizumab (avastin) (Roche) was labeled with 
DyLight 550 antibody labeling kit (Thermo Scientific) following the instructions of the 
manufacturer. For capture, 20 µL hydrogels were formed in presence and absence of ZZ-Lys 
directly in eppendorf tubes, after 30 minutes 500 µL SFM (devoid of phenol red) containing 500 
ng/mL labeled sFLK-FC and 50 µL of supernatant was withdrawn and substituted with fresh 
medium for one week at the indicated time points. As a control, medium was added to tubes 
without hydrogels. For release, 20 µL of hydrogels with and without ZZ-peptide and 100 ng 
labeled sFLK-FC or bevacizumab, respectively was directly polymerized in eppendorf tubes and 
after 30 minutes 500 µL of SFM was added and incubated for one week at 37˚C. The medium 
was replaced completely at the indicated time points. As a control 100 ng of labeled protein was 
added to 500 µL SFM without a hydrogel. For determination of remaining or released labeled 
protein the supernatants were measured with the plate reader Synergy H1 at emission/excitation 
526/576 nm and normalized to the controls. 
 
Characterization of hydrogels generated with copper alloy 
Single and bi-layered hydrogels generated with different concentrations of HSA (0-500 µM) and 
25 µM Cy3-Lys were imaged in a drop of tris buffer on a glass slide by confocal scanning laser 
microscopy (LSM710, Zeiss). Z-stacks with 30 µm distance were taken from top to bottom in the 
middle of the hydrogel with the 10x objective. The average fluorescent Z-intensity was extracted 
with ImageJ and normalized to the intensity measured in control hydrogels that were prepared 
between two glass slides in order to compensate for the fluorescence loss in deeper layers.  
 
Ectopic implantation in mice  
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Gel constructs without any in vitro culture unless stated differently in the text were implanted in 
subcutaneous pouches (four per animal) in the back of female athymic CD-1 nu/nu mice 
(Charles River Laboratories), >5 weeks of age. Animals were sacrificed for construct retrieval 
after 2, 3, 4, 8 or 12 weeks as stated in the text. All animal procedures were reviewed and 
approved by the Swiss Federal Veterinary Office (BS 1797).  
 
Cytofluorometry and fluorescently activated cell sorting (FACS) 
BMSCs at different passages were analyzed using the fluorophore-conjugated antibodies 
against the following surface markers: CD49a, mouse CD8 (Becton Dickinson), CD56, CD105, 
CD106, CD166 (BioLegendes). The cells after trypsinization were stained for 20 minutes at 4°C 
in FACS buffer (PBS, 2 % FBS, 2.5 mM EDTA) and measured with a Fortessa flow cytometer 
(Becton Dickinson). The data was processed in FlowJow. For sorting, the cells were trypsinized 
and stained in FACS buffer for 20 minutes at 4°C with an anti CD56-APC, (BioLegends) or an 
anti mouse-CD8a-APC antibody (Becton Dickinson) and sorted using Aria (Becton Dickinson). 
3.3x103 unsorted, negatively and positively sorted cells/cm2 were plated and expanded until 
confluent or not more than 12 days before testing in chondrogenic assays.  
 
Quantification of glycosamino glycan (GAG) and DNA 
Pellets and hydrogels were digested with 1mg/mL protease K in 50 mM Tris with 1mM EDTA, 
1mM iodoacetamide and 10 mg/mL pepstatin-A for 16 h at 56° C. For glycosaminoglycan 
quantification, the method of Barbosa et al. [223] was employed. Briefly, diluted or undiluted 
digested constructs (depending on SafO intensity) were incubated with 1 ml of DMMB solution 
(16 mg/L dimethylmethylene blue (DMMB), 6 mM sodium formate, 200 mM GuHCL, pH 3.0) on 
a shaker at room temperature for 30 minutes. Precipitated DMMB-GAG complexes were 
centrifuged and supernatants were discarded. Complexes were dissolved in decomplexion 
solution (4 M GuHCL, 50 mM Na-Acetate, 10% Propan-1-ol, pH 6.8) at 60°C, absorption was 
measured at 656 nm and GAG concentrations were calculated using a standard curve prepared 
with purified bovine chondroitin sulfate. DNA content was measured by using the CyQuant® Cell 
Proliferation Assay Kit (Molecular Probes) according the instructions of the manufacturer. 
 
Histological and immunofluorescence staining 
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Pellets and hydrogels after in vitro culture or upon explantation, respectively, were fixed in 4 % 
paraformaldehyde, dehydrated, embedded in paraffin with the help of histogel (Thermo 
Scientific) and 5 µm thick sections were cut (Microm HM 430 or Microm HM 340E).  
Alternatively, fixed hydrogels were frozen in O.C.T. (VWR) with the help of a cartridge filled with 
methylbutane and dipped in liquid nitrogen and 7-10 µm thick cryosections (Cryostat Leica 
CM1950) were made. In vivo samples after fixation were decalcified in 15 % EDTA, pH 7 if 
required. Safranin-O/fast green staining with hematoxylin (J.T. Baker) nuclear counterstaining 
was performed to analyze chondrogenic and bone tissue formation. For semi-quantitative 
assessment of chondrogenesis the Bern score according to Grogan et al. [224] was determined. 
For immunofluorescence (IF) or immunohistochemical (IHC) staining after dehydration, the 
sections were subjected to enzymatic epitope retrieval at 37˚C first with 2 mg/mL hyaluronidase 
and then with 1 mg/mL pronase (Roche), blocked with 5 % bovine serum albumin and the 
following primary antibodies were used: ColI, human specific, ab138492; ColI, mouse-specific, 
ab21286; ColII, human and mouse specific ab34712; ColX, human specific, ab49945, BSP, 
ab52128 and GFP, ab6673 (abcam). The immunobinding was detected in the case of IF with 
Alexa Fluor 488 or 564 conjugated secondary antibodies (Invitrogen) and DAPI was used as a 
nuclear counterstain, and for IHC with biotinylated secondary antibodies (Dako), the 
VECTASTAIN® ABC kit (vector laboratories) and VECTOR Red Alkaline phosphatase substrate 
kit (vector laboratories) for detection, hematoxylin (J.T. Baker) was used as a counterstain. For 
ColX staining in order to reduce mouse background staining, the primary antibody was pre-
incubated with double the concentration of goat derived anti-mouse Fab fragments (Jackson 
Immuno Research) for 20 minutes and blocked with 10 % normal mouse serum (Jackson 
Immuno Research) for 10 minutes following the technique of [225]. The sections were visualized 
using a wide field microscope (Olympus BX61 or BX63) and images were processed with 
ImageJ. For semi-quantitation of the in vivo differentiation efficiency of single layered hydrogel 
constructs, SafO/FG stained sections were assigned with a score between 0-3 based on the 
criteria of bone in Table 3. For double-layered constructs the scoring based on SafO/FG stained 
sections and GFP labeling, was divided into evaluation of the cartilage part (identified by the 
prevalent presence of GFP-positive cells) and the bone part (identified by the absence of GFP-
positive cells) by a number of 0-3 and an additional value of one was assigned if the constructs 
kept a bi-phasic configuration, resulting in a maximum score of 7 (Table 3).  
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Part Parameters Score 
Cartilage Undifferentiated/ fibroblastic 0 
 Hypertrophic cartilage 1 
 Mix of hyaline-like and hypertrophic cartilage 2 
 Hyaline-like cartilage 3 
Two-layer  Two layers disassembled or bi-phasic configuration lost 0 
configuration Bi-phasic configuration visible 1 
Bone Undifferentiated/ fibroblastic 0 
 Hypertrophic cartilage 1 
 Cartilage under remodelling 2 
 Cortical bone and bone marrow 3 
 Maximum 7 
Table 3: Parameters included in the histological scoring of double layered constructs.  Based on the SafO/FG 
staining and GFP immunofluorescence the bone and the cartilage part were evaluated with a number from 0-3, 
respectively and the interface between 0-1, resulting in a maximum score of 7. Hyaline cartilage score for the cartilage 
part was only assigned if there was no hypertrophic cartilage tissue was present at all. 
 
RNA sequencing 
Based on SafO/FG staining the clones were evaluated and divided into two groups, clones with 
a Bern score ≥ 3 were classified to have a high CC and clones with a Bern score < 3 as clones 
of low CC. The batch 1 analysis included 14 clones of donor 1 (6 of high CC) and batch 2 seven 
clones of donor 2 (3 of high CC), eight of donor 3 (4 of high CC) and six clones of donor 4 (3 of 
high CC). For mRNA isolation the protocol of the column-based quick-RNA min-prep 
(ZymoResearch) was followed. mRNA was quantified by using nanodrop and its quality was 
determined with the help of the 2100 bioanalyzer (Agilent technologies). 300 ng of DNase-
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digested mRNA was used for library preparation with TruSeq Stranded Total RNA Kit with Ribo-
Zero Gold (Illumina). Libraries were run on the fragment analyzer (Advanced Analytical) for 
quality control and were adjusted to equal concentrations. Sequencing was performed with a 
HighSeq 2500, with single end reads of 50 base lengths. The data was analyzed in R with the 
help of the Bioconductor package for determination of differentially expressed genes considering 
the chondrogenic capacity of the clones. All genes with an adjusted P-value <0.05 were 
considered to be significantly differentially expressed. For batch 1 two different approaches were 
tested: only a sub-set of clones was compared based on similar proliferation rates or all clones 
were analyzed in an unbiased way without accounting for the proliferation rate. For batch 2, the 
data were analyzed without considering the proliferation rate and the donors were considered as 
co-variable. The significantly differentially expressed genes of the subset analysis of batch 1 
were additionally compared to the panel of QUIAGEN surface markers to identify surface 
markers and to identify involved pathways analyzed by ingenuity pathway analysis (QUIAGEN). 
 
Quantitative real-time PCR 
The mRNA was isolated as described in the RNA sequencing paragraph except that the DNA 
digestion was not performed. cDNA was generated with random primer (Promega) and the kit of 
SuperScript reverse transcriptase III (Thermo Scientific). For qPCR the TaqManTM assay on 
demand system based on FAM and Tamra (Thermo Scientific) was used. Samples from the 
clonal studies and the sorting experiments were analyzed for expression of CD56 (NCAM1) 
(Hs00941830) and as reference gene GAPDH (Hs02758991) was used. PEG hydrogel samples 
from in vivo and in vitro experiments were digested for 45 minutes in 0.15 % type II collagenase 
(Worthington) at 37˚ C prior to RNA isolation. They were analyzed with the following TaqManTM 
primers: ColI (Hs00164004), ColII (Hs00264051), ColX (Hs001666657), VEGFA (Hs00900055), 
chondromodulin (Hs0017087). 
 
Statistical analysis 
Statistical analysis was performed with Graph Pad Prism 6 software. Statistical significance was 
considered with a P-value < 0.05. All the data are shown as average +/- standard deviation. N 
indicates number of donors tested and analyzed.  
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